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RÉSUMÉ 
Après avoir réussi à propulser des agents thérapeutiques encapsulés dans des micro-transporteurs 
magnétiques à un endroit précis à l'intérieur d'un modèle animal en utilisant le gradient de champ 
magnétique dans un appareil de résonance magnétique (RM) modifié, nous visons maintenant à 
livrer une drogue localement dans le système nerveux central (SNC). Afin de réussir la livraison 
de la drogue de façon localisée et augmenter l'efficacité du traitement, ce projet met de l’avant 
que les agents thérapeutiques doivent être administrés par des moyens pas plus envahissants 
qu’une injection intraveineuse, suivis par la propulsion à distance, contrôlée, et actionnée sur 
commande dans le SNC. 
La fonction exigeante du tissu neuronal dans le SNC (haute sensibilité/complexité du système) 
nécessite un environnement extrêmement stable. Un changement minime dans la composition du 
liquide interstitiel dans le SNC peut jouer un rôle prépondérant dans la régulation de son 
microenvironnement et de l'activité neuronale. Par conséquent, le SNC est conçu pour se protéger 
des fluctuations fréquentes de la concentration extracellulaire d’hormones, d’acides aminés, et 
des niveaux d'ions produits après les repas, l'exercice ou le stress (ainsi que d'agents pathogènes 
toxiques qui peuvent être en circulation dans le sang). Cette protection du SNC est permise grâce 
à la présence d’une barrière, nommée barrière hémato-encéphalique (BHE). Cette barrière 
préventive se compose essentiellement de cellules endothéliales étroitement reliées entre elles qui 
tapissent la surface intérieure de la plupart des vaisseaux sanguins dans le SNC. Bien que ceci 
offre un environnement neuronal stable, plus de 98% des molécules que constituent les drogues 
ne sont pas en mesure de franchir la BHE et leur pénétration est uniquement déterminée par les 
caractéristiques de perméabilité de la barrière. Ceci est alors un frein pour les traitements ciblant 
le SNC. Par conséquent, la recherche pharmaceutique fait un réel effort pour maximiser la 
livraison des médicaments vers le SNC. Pour autant, la présence des barrières physiologiques, 
bien qu’essentielles à la survie en conditions physiologiques, limitent les traitements qu’on a à 
notre disposition en conditions pathologiques. La perspective thérapeutique novatrice détaillée 
dans cette thèse est d’ouvrir localement et transitoirement la BHE pour permettre aux drogues 
thérapeutiques de diffuser au sein du SNC. Cette technique pourrait fortement augmenter la 
possibilité de traiter divers troubles neurologiques dans le cadre clinique. 
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Au niveau préclinique, nous proposons ici d’utiliser des nanoparticules magnétiques (NPM), 
mises de pair avec un champ magnétique alternatif. Le but étant d’augmenter la perméabilité de 
la barrière pour livrer une drogue de façon transitoire. Les NPM peuvent agir comme des sources 
de chaleur miniaturisées qui, sous l'influence du champ magnétique alternatif, dissipent de 
l'énergie thermique directement et exclusivement à la barrière (hyperthermie). En plus de cette 
nouveauté, les résultats confirment que cette technique ne porte pas atteinte à l'unité 
neurovasculaire, comme les neurones, les astrocytes, etc. Cette expérience in-vivo démontre que 
l'approche proposée va au-delà d’anciennes méthodes utilisées pour accéder au tissu du SNC. 
Notamment, une précision spatiale plus élevée, un meilleur contrôle et l'absence apparente de 
réaction immunitaire. L'ensemble des capacités de suivi et de mobilité (technologie RM), ainsi 
que l'hyperthermie, combinés, permettent aux NPM (composant principal du mécanisme de 
délivrance de médicament) d’être livrées au SNC de façon non-invasive. En raison de sa 
simplicité et de sa spécificité, cette technique peut entraîner d’énormes impacts économiques et 
sociaux au niveau de la qualité de vie des patients diagnostiqués avec des troubles liés au SNC. 
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ABSTRACT 
After successfully propelling therapeutic agents encapsulated in magnetic micro-carriers to a 
specific location inside an animal model by the gradient magnetic field of a modified clinical 
Magnetic Resonance (MR) scanner, we are now aiming to perform local drug delivery in the 
region of the central nervous system (CNS). To achieve localized drug delivery and increase 
efficacy, this project advances the theme that the therapeutic agents must be administered by 
means no more invasive than an intravenous injection followed by remote propulsion, controlled 
tracking, and on-command actuation in the CNS. 
The demanding function of the CNS requires an extremely stable environment. In fact, any small 
change in the composition of the interstitial fluid in the CNS plays a predominant role in 
regulating its microenvironment and neuronal activity. Therefore, the CNS is conceived to 
protect itself from frequent fluctuations of extracellular concentration of hormones, amino acids, 
and ion levels that occur after meals, exercise, or stress - as well as from toxic pathogens that 
may be circulating in the blood stream. This preventive barrier consists mainly of tightly 
interconnected endothelial cells that carpet the inner surface of most blood vessels in the CNS. 
While it provides a stable neuronal environment, more than 98% of all drug molecules are not 
able to cross this barrier and the extent to which a molecule enters is determined only by the 
permeability characteristics of the barrier. Therefore, while pharmaceutical research progresses 
for drug delivery to the CNS, it is limited by its pharmacokinetics through physiological barriers. 
Successful transient and local opening of the barrier for diffusion of therapeutics could strongly 
support the feasibility of treating a variety of neurological disorders.  
A recent effort presented in this dissertation provides evidence for the emergence of a novel 
approach to overcome this problem. This technique uses magnetic nanoparticles (MNPs) in 
conjunction with an alternating magnetic field to transiently increase barrier permeability for 
drug delivery. MNPs can act as miniaturized heat sources that, when under the influence of the 
alternating magnetic field, dissipate thermal energy directly and exclusively to the barrier 
(hyperthermia). In addition to its novelty, the findings confirm that the technique does not 
damage the neurovascular unit, i.e. neurons, astrocytes, etc. This in vivo investigation provides 
evidence that the proposed approach goes beyond former methods to access the CNS tissue with 
higher spatial precision, advanced control and apparent absence of immune reaction. Evidently, 
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the ensemble of tracking and displacement abilities (MR technology), as well as hyperthermia, 
makes MNPs a principal component of the proposed non-invasive targeted drug delivery 
mechanism to the CNS. Because of its simplicity and specificity, this technique can introduce an 
enormous economical and social impact on quality of the life of patients diagnosed with CNS-
related disorders.  
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CHAPTER 1 INTRODUCTION 
The emergence of a clinically viable targeted drug delivery technique for the Central Nervous 
System (CNS) can have a profound impact on the life of millions of people around the world. In 
this essential and complex collective-dream technique, therapeutics are monitored and propelled 
inside the vasculature of the patient towards a region of interest. Once at the target, the 
therapeutic molecules actively cross into the CNS and locally combat the malignancies at play. 
To orchestrate this important venture, it is absolutely crucial that the multidisciplinary team of 
researchers work in harmony. To achieve this harmony, it is essential to be aware of constrain in 
all aspects of the project and compromise accordingly. Therefore, while other members of the 
team research monitoring and propulsion of therapeutics in the vasculature, the present doctoral 
thesis focuses on therapeutics traversing from the vascular system to the parenchymal tissue of 
the CNS.  
1.1 Introductory concepts 
According to the latest report from the world health organization (WHO) [1], neurological 
disorders constitute the highest percentage of the global burden of disease (6.3%). This has 
contributed to 92 million disabilities in 2005 and it is projected that this number will increase to 
103 million in 2030. These disorders include brain tumour. According to the brain tumour 
foundation of Canada [2], it is estimated that every day 27 Canadians are diagnosed with a brain 
tumour. Among these, the first and second year relative survival rates for some brain tumours 
such as the glioblastoma multiforme (GBM) are reportedly 29.6% and 9.0%, respectively [3]. 
Another example of an aggressive tumour that occurs in the developing retina of children is 
retinoblastoma. The worldwide incidence of this type of tumour is about 9,000 new cases every 
year [4] and it can lead to death within 1-2 years if left untreated. This extremely low life 
expectancy is due to high cytotoxic side effects of the therapeutic molecules on healthy cells, and 
of course low penetration rate of the medication to the CNS that subsequently leads to increase in 
dosage and therefore higher cytotoxic side effects. A preventive barrier that carpets the inner 
layer of most capillaries in the CNS is inarguably responsible for the lack of effective penetration 
of therapeutics in the tissue. While the main function of this selectively permeable barrier is to 
2 
 
protect the sensitive microenvironment of the CNS, overcoming it would have a great effect on 
the treatment of many CNS-related disorders. 
1.2 Hypothesis and goals 
In this doctoral dissertation, a novel technique for local delivery of large therapeutic molecules to 
the CNS is hypothesized and investigated. This technique is based on local elevation of 
endothelium temperature – hyperthermia – by magnetically excited magnetic nanoparticles 
(MNPs). Studies of the CNS barrier under hyperthermia have subsequently provided evidence 
that upon application of a radiofrequency magnetic field, the thermal energy released from MNPs 
can remotely, locally, and transiently increase barrier permeability in a rat model. There are many 
advantages to the proposed technique over others used to deliver therapeutics to the CNS; 
hyperthermia of MNPs operates at relatively low focal temperatures (maximum of 41 °C) and the 
heat is dissipated uniquely to the surface of the endothelial cells without compromising other cell 
types in the neurovascular unit (neurons and glia). Also, the barrier opening process is transient, 
as it has shown complete recovery within two hours. In addition, the use of the radiofrequency 
magnetic field to heat the MNPs makes this technique very effective in deep biological 
structures. Finally, this technique can easily be adapted to the monitoring and propulsion 
techniques already developed by other members of the team for targeted drug delivery [5].  
Magnetic properties of the MNPs with respect to hyperthermia were previously investigated and 
presented as a master’s degree dissertation [6]. In this doctoral thesis, the objective is to apply the 
findings to open CNS barrier in a rat model. This work is done in 3 phases:  
Phase 1, a proof of concept with the use of an external heating apparatus on the skull of an 
anaesthetized mouse. 
Phase 2, transient opening of the CNS barrier in the brain parenchyma with MNPs in a rat model.  
Phase 3, enhanced targeting and opening of the CNS barrier in the retinal tissue with MNPs 
coated with transferrin in a rat model. 
In this presentation, there will be a brief section on the theoretical background of the proposed 
technique (Chapter 2), followed by the project rationale (Chapter 3), and published peer-review 
articles (Chapter 4 and Chapter 5). The latest results on disruption will be presented in Error! 
Reference source not found., followed by a general discussion (Chapter 7) and conclusion. 
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CHAPTER 2 THEORETICAL BACKGROUND 
2.1 CNS barrier 
The inner lining of all capillaries in the mammalian body including humans are composed of 
endothelial cells [7]. With the exception of those in the CNS, the capillaries are fenestrated to 
allow for rapid exchange of molecules between blood vessels and surrounding tissue. In the CNS 
very complex inter-endothelial tight junctions interconnect the endothelial cells (Figure 2.1). The 
tight junctions seal the cell interspace and form a diffusion barrier that markedly controls the 
flow of molecules across the epithelium. This unique vascular structure greatly contributes to the 
blood-brain barrier (BBB) in the brain and the blood-retinal barrier (BRB) in the ocular organ. A 
functioning BBB limits the passage of microscopic organisms (bacteria, viruses, etc.) and large or 
hydrophilic molecules into the cerebrospinal fluid while allowing diffusion of small electrically 
neutral lipid-soluble compounds with low molecular mass of less than 400-500 Daltons (Da) [8]–
[10]. This barrier also keeps the neurotransmitters and agents that act in the CNS separate from 
the peripheral tissue and the blood, so that similar agents can be used in the two systems without 
‘crosstalk’ [11]. Similarly, the BRB maintains the specialized environment of the retina and 
provides necessary nutrients to the eye while protecting it from toxic pathogens that may be 
circulating in the blood stream. By extension, more than 98% of acting biomolecules, including 
most anticancer drug molecules and available therapeutics are not able to reach the CNS 
following systemic administration [7], [12]. On the other hand, systemic administration of drugs 
causes the active principles to distribute throughout the body and organs and may promote side 
effects. The highly selective permeability of BBB and BRB, and the cytotoxicity of certain drugs 
reinforce the importance of non-invasive localized drug delivery to the CNS.  
The BBB and the BRB are very sensitive to a broad spectrum of physiological changes that are 
manifest as detectable leaks of molecules from the blood into the extracellular compartment of 
the CNS. While manipulating the barrier is essential to drug delivery, consequences of increased 
barrier permeability may lead to accumulation of unwanted molecules and concomitant 
disruption in normal CNS function. In order to minimize subsequent risks, it is highly 
recommended that the CNS barrier opening technique be localized, transient, and immune-
friendly.   
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Figure 2.1: Schematics of a single capillary in the CNS 
The capillaries in the CNS mostly consist of endothelial cells that are tightly interconnected and form a selective 
barrier. It protects the CNS from intrusive substances that could harm or alter CNS functionality. However, this also 
includes most drug molecules to enter the CNS.  
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2.2 Drug delivery to CNS 
Drug delivery to the CNS remains a challenge mainly because the tightly interconnected 
endothelial cells (tight junctions) constitute a barrier that is reputed to be insurmountable. 
Following systemic administration, a functioning BBB in the brain and the BRB in the eye 
prevent entry of nearly 98% of drugs such as peptides, recombinant proteins, monoclonal 
antibodies, antisense and non-viral gene medicines to combat brain and ocular related disorders 
[7], [12], [13]. Due to the large surface area of the BBB (180 cm2
 
per gram brain [10]), as well as 
the short diffusion distance between neurons and capillaries (8 – 20 µm [14]), the extent to which 
a molecule enters the brain is determined only by the permeability characteristics of the BBB. 
Similarly, drug delivery across the BRB in the highly dense microvasculature of the retina faces 
the same restriction. Current popular drug delivery strategies to the brain may be classified as 
being either invasive (Table 1) or non-invasive (Table 2). The invasive approaches require either a 
craniotomy, intracerebro-ventricular (ICV) infusion of drugs, or intra-cerebral implants. The non-
invasive drug delivery approaches include physiological stimuli (insulin or transferrin receptor 
mediated transcytosis), chemical stimuli (prodrug approach such as antibody directed enzyme 
system) [15], biological stimuli (molecular Trojan horse approach) [16], and physical stimuli 
including colloidal carrier system techniques (self microemulsifying / nanoemulsifying drug 
delivery systems) [12]. Likewise, ocular drug delivery approaches across the BRB consist of an 
invasive intravitreal, intracameral, posterior juxtascleral, or retrobulbar injection of the 
medication into the eye, and the non-invasive (relative to surgery) approaches include application 
of high drug dosage through topical, oral, systemic, or sub-tenon administration [17].  
Despite encouraging results presented in some preclinical models, clinical trials using these 
approaches have been less promising. The results vary from increased normal tissue toxicity or 
complete or partial lost of vision to only small increase in patients’ survival rate. That is because 
either the approach is extremely harsh for the sensitive CNS microenvironment (ICV or 
intravitreal approach), or it is specific to a small group of drug molecules (molecular Trojan horse 
approach). Nevertheless, recent developments using physical stimuli have drawn lots of attention.  
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Table 1: Invasive brain drug delivery methods 
 
Intranasal Drug 
Administration 
Diffusion of small lipid-soluble molecules from the submucous spaces of the nose to the 
brain through the epithelial barrier [10]. 
Intracerebral 
Implants 
Implantation of genetically engineered cells or biodegradable polymers in the brain. 
Minimal drug administration due to poor penetration (approximately 1 mm) into the 
tissue [18]. 
Convection-
Enhanced diffusion 
Effective for brain tumours yet extremely invasive neurosurgical-based technique 
involves the intracerebral infusion of fluid through the brain tissue [10]. 
Intracarotid arterial 
infusion 
Solvents or agents such as vasoactive molecules, alkylating agents, cold saline, free fatty 
acids, and high dosage ethanol can presumably cause BBB disruption. They generally 
involve harsh applications [10]. 
 
Table 2: Non-localized minimally to non-invasive brain drug delivery methods 
Lipidization Addition of lipid groups to increase permeability 
Nano-carriers Employment of nano-sized particles to infiltrate large molecules through the BBB [19], [20].  
Endogenous 
transports 
Chemical modification of drugs to deceive the BBB, such as in Trojan horse technique 
[21]. 
Osmotic opening 
Exposing of the BBB to a hyperosmolar solution causes the endothelial cells to shrink 
and place a reversible stress on the tight junctions by pulling them apart. Therefore, 
temporarily the BBB is considered “open” [22]. 
 
 
2.3 Physical stimuli for CNS drug delivery 
Physical stimulation of the vessels, endothelial cells, and the tight junctions can indeed promote 
vascular leakage and may facilitate drug diffusion into the CNS.  
2.3.1 High intensity focused ultrasound 
High intensity focused ultrasound (HIFU) is among recent techniques that promise increase in 
BBB permeability as well as localized control [23]. This technique employs an acoustic energy to 
vibrate intravenously administered micro-metric lipid-encased perfluorocarbon gas microbubbles 
(MBs) near the target endothelium. The oscillating MBs create a mechanical stress on the 
endothelial tight junctions thus allowing therapeutics to enter the brain [24], [25]. Despite its 
enhanced synergistic effects, MBs have short half-lives in the vasculature and are quickly up-
7 
 
taken by the reticuloendothelial system when circulating through the liver. Furthermore, 
oscillating MBs undergo a phenomenon that leads to formation of high-pressure shock waves as 
well as fast-moving liquid jets [26], which can seriously damage the cellular membrane near rigid 
surfaces in the brain. Also, the sound waves propagate non-linearly over a large region of 
biological structures before converging into a focal point, which may lead to undesirable side 
effects. While recent efforts claim to have increased efficacy by conjugating MBs with MNPs 
[27], HIFU offers low spatial and temporal resolution for drug delivery to the brain. This is 
mainly because the acoustic energy propagates non-linearly over a broad region of biological 
structures before converging into its relatively large focal point (1 × 1 × 7 mm3 [23]). Similar to 
light waves, sound waves follow laws of reflection and refraction. Therefore, sudden variation in 
the acoustic impedance of the skull from that of the adjacent soft tissue can lead to reflection of 
the energy and thus promote intolerable change of temperature in the brain and on the surface of 
the skull [28].  
2.3.2 Magnetic targeting 
Magnetic targeting is another technique that over the years has drawn the attention of many 
researchers. In this technique drug molecules are loaded with MNPs and the complex is 
magnetically propelled to a target and then pulled across the CNS barrier using an external 
permanent magnet or an electro-magnet located near and above a biological target site. However, 
in a recent study [29], despite what the authors claim, the MNPs seem to injure the surface of the 
cellular membrane while being pulled across the barrier. Also, due to higher field intensity near 
the external magnet (higher gradient), targeting is mostly restricted to superficial areas near the 
skin. Furthermore, this technique lacks concurrent systematic navigational control when 
employed in the complex microvascular structures of the brain and may not be suitable for CNS 
drug delivery. Nevertheless, development of a complementary approach that employs the 
attractive magnetic targeting technique with imaging capabilities, transient opening effect on 
CNS barrier, and compatibility with CNS immune system is demonstrated to have merit. 
2.3.3 Hyperthermia 
In modern oncology, hyperthermia – otherwise known as elevation of body temperature – refers 
to heating of organs or tissues in various ways to temperatures between 40 °C and 45 °C, at 
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which point it causes moderate and reversible cellular inactivation [31]. This heat can 
preferentially lead to the death of cancer cells by enhancing cell sensitivity and vulnerability 
towards more established forms of cancer therapy, such as radiation and chemotherapy.  
The effects of heat on CNS barrier and its microcirculation are but one example of the complex 
interaction between heat and the CNS circulation. Hyperthermia above 43 °C can cause vascular 
damage, increase in membrane permeability, and increase in cerebral blood flow. Subsequently, 
these in turn lead to cerebral ischemia, release of various neurochemicals, and increase in 
glutamate neurotoxicity [32]. The molecular mechanism of hyperthermia-induced CNS barrier 
leakage is not entirely understood; nevertheless, mild hyperthermia (below 40 °C) constitutes 
intense cellular stress and causes reversible disruption of the CNS barrier [33]. Studies suggest 
that the morphological changes of individual endothelial cells in the monolayer lining of the 
microvessels are necessary for the tight junctions between adjacent endothelial cells to loosen 
thereby allowing transport of large molecules through intercellular pathway [34]. During local 
and mild hyperthermia, systematic blood flow and movement of the interstitial fluid in the 
microenvironment, prevents healthy cells from overheating [35]. In these conditions, 
hyperthermia redirects protein synthesis in the cells to produce heat-shock proteins, increases the 
membrane fluidity, and changes the vesicular and tubular components of microvascular 
endothelial cells [36]. An interesting observation by scientists is that cells undergo a conditioning 
phenomenon that renders them capable of adapting to heat in order to survive [37]. Heat shock or 
stress conditions experienced by cells and tissues alters cell structure and function in a 
homeoviscotic manner and render them more resistant to further stress. Therefore, cells can build 
tolerance to the damaging effects of temperature if they are gradually and repeatedly heated [36], 
[38]. After cessation of mild hyperthermia, tight junctions commence to recover [39] and their 
recovery rate depends on the amount of heat and exposure time. 
2.4 Hyperthermia of MNPs 
While conventional hyperthermia methods such as whole body hyperthermia [40], high intensity 
focused ultrasound [41], radio frequency [42], and microwave [33], [43] have been applied to 
allow certain molecules to cross the CNS barrier, they do not have spatial precision and they are 
not effective in deep structures of the brain. In addition, these techniques adversely affect the 
cerebrovascular unit. In other words, these remedies modify the barrier functionality as well as its 
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surrounding biological entities such as neurons, astrocytes and glial cells. This widespread 
heating can induce many undesirable acute side effects.  
To address the above-mentioned setbacks, the proposed alternative method is based on 
hyperthermia of MNPs by an external alternating magnetic field. In this configuration, an 
alternating magnetic field remotely excites the MNPs at a desired target vasculature in the CNS. 
The generated heat from the MNPs is then dissipated directly to the surface of the endothelium 
resulting in brief barrier leakage.  
2.4.1 Advantages of using MNPs for hyperthermia 
In order to make CNS drug targeting a clinically viable technique, one has to propel drug 
molecules towards the target and control their motion via an imaging modality. This is indeed the 
basic idea behind the magnetic resonance navigation (MRN) project [30]. In this approach, 
micro-carriers composed of drug molecules and aggregates of MNPs are used to navigate inside 
small capillaries. The MRN provides physicians with a platform that allows targeting and 
delivery of medications to any specific location in the human body. In this design, MRN relies on 
a clinical magnetic resonance imaging (MRI) scanner to navigate the micro-carriers along a pre-
determined suitable vascular route on their journey towards the target.  The MNPs function as 
MRI contrast agents and provide the capability to assess the targeting efficacy through imaging 
sequences. Biocompatible iron-oxide superparamagnetic nanoparticles used in MRN have 
already been proven effective to orchestrate monitoring and steering in the MRI to deliver 
therapeutic agents through a suitable vascular route. Hyperthermia of MNPs therefore, 
complements the already successful MRN system for the purpose of drug delivery to CNS. In 
addition, hyperthermia operates at relatively low focal temperatures (maximum of 39 °C) and the 
heat is dissipated directly and uniquely to the surface of the endothelial cells without 
compromising the neurovascular unit (neurons and glia). Moreover, blood flow and movement of 
the interstitial fluid in the brain microenvironment will further help prevent other sensitive 
structures in the CNS from overheating [14]. The low focal temperatures also help accelerate the 
recovery process and the return to the status quo for the tight junctions. Furthermore, the 
radiofrequency magnetic field allows this technique to be effective in deep biological structures 
of the CNS, especially in the brain. Last but not least, specific surface coating of the MNPs can 
increase particle affinity to the endothelium and thus enhance thermal delivery and efficiency. 
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For instance, transferrin, a single-chain of glycoproteins, has receptors that are unregulated on 
both the endothelium [44], and on the surface of many cancer types, including glioblastoma and 
retinoblastoma. Therefore, transferrin conjugated MNPs (Tf-MNPs) are excellent candidates to 
target the CNS barrier [15]. 
2.5 Physics of hyperthermia of MNPs 
The thermal energy generated by magnetic materials inside of an alternating magnetic field is 
mainly caused by three major mechanisms; hysteresis loss, Néel and Brownian relaxations. 
Particle size, shape, composition, concentration and viscosity of the suspension medium as well 
as magnitude and frequency of the applied alternating magnetic field determine the relative 
strength of each of these mechanisms. In this section, details of scenes behind magnetic heating 
(hyperthermia) are explained. 
2.5.1 Magnetic Domains 
In order to minimize magnetostatic energy of the material, large magnetic materials consist of 
several domains. The magnetostatic energy is the energy of the magnet in its own field. As shown 
in Figure 2.2 [45], by splitting the crystal into several domains, the spatial extent of the 𝐇 field 
decreases. This is because as the number of domains increase, the north and the south poles 
become closer and therefore it reduces magnetostatic energy of the material. 
 
Figure 2.2: Magnetostatic energy reduces as crystal is split into domains 
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The boundary separating the two neighbouring domains is called a domain wall. Each domain 
contains large numbers of atomic magnetic moments, m created by microscopic current related to 
the spin of the electrons. Indeed, all materials are classified by the orientation of their magnetic 
moments and form various types of magnetism mainly known as ferromagnetism, 
ferrimagnetism, antiferromagnetism, paramagnetism and diamagnetism. The complete theory of 
magnetism is well beyond the scope of this introduction. However, Figure 2.3 [45] illustrates the 
orientation of the magnetic moments for these types of magnetism.  
Magnetic moments of ferri-, ferro- and antiferromagnetic materials are aligned with each other 
below a critical temperature – the Curie temperature – to reduce the exchange energy of the 
material. The exchange energy is caused by the interactions among internal magnetic moments. 
According to the Weiss domain theory [47], the direction of the aligned moments varies from 
domain to domain, and in the absence of an external magnetic field this direction is aligned along 
magnetic crystallographic axes called ‘easy axes’. In fact, domain walls consist of smooth 
gradual rotation of the direction of the m vectors within the crystal shown in Figure 2.4 [45].  
 
 
Figure 2.3: Different types of magnetism [45] 
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The spin-orbit coupling, meaning interaction between spin and the orbital motion of each 
electron, exhibits a resistive force against any attempt by an external magnetic field to rotate the 
spin axis. The energy required to overcome the spin-orbit coupling that keeps particles 
magnetized in a specific direction is called anisotropy energy, E = KV, where K is the effective 
anisotropy constant and V is the volume of the magnetic core [45], [48]. The anisotropy constant 
is a sum of several terms such as magnetocrystalline, shape and surface anisotropy as well as 
dipole-dipole interaction between the crystals [49]. Here, it is assumed that the MNPs have 
spherical shapes and are mono-dispersed in solvent with low volume fractions. Therefore, 
magnetocrystalline and surface anisotropy contribute the most to the effective anisotropy 
constant of MNPs. 
 
Figure 2.4: Presentation of domain wall [45] 
As the external magnetic field strength increases, the net m vectors of the domains of a ferri- and 
ferromagnetic material become more aligned with the external magnetic field direction to 
minimize the crystal potential energy and cause displacement of the domain walls. Figure 2.5 
[45] shows that as the external field strength becomes larger, the magnetic moments opposing it 
become smaller. If the external field is high enough, it can align all m vectors to the magnetic 
field direction and the material can act as a single domain particle with a unidirectional magnetic 
moments. 
 
Figure 2.5: Multi-domain material inside applied external magnetic field [45] 
13 
 
In this investigation, ferrimagnetic iron oxide (magnetite) nanoparticles were chosen. As shown 
in Figure 2.3, these nanoparticles display lower magnetic response compare to ferromagnetic 
materials. This is because a ferrimagnetic material consist of m vectors that are not all aligned in 
one direction, therefore, the net m vector is smaller than that of a ferromagnetic material where 
the m vectors are all aligned in one direction. However, in addition to magnetite biocompatibility 
and low toxicity advantages, these particles are less sensitive to oxidation than ferromagnetic 
materials and therefore maintain stable magnetic behaviour [46] in rich oxygen environments 
such as in a human body.  
2.5.2 Hysteresis 
The energy from exposure to moderate external field H (Figure 2.6 point 1) [45] leads magnetic 
moments to overcome the anisotropy energy. This results in an irreversible sudden rotation of the 
magnetic moments into a new set of magnetic crystallographic axes. These axes are nearest to the 
external field direction. The directions of the moments within domain walls are indeed a balance 
between exchange and anisotropy energies. Therefore, a change in the external field energy can 
alter this balance and cause moments to rotate. Further increase in field amplitude leads to 
saturation of magnetization MS of the magnetic moments (Figure 2.6 point 2) and a reversible and 
gradual alignment with the external field direction and hence creation of a sample that acts as a 
single domain [47]. The MS value for a bulk matter is different for nanoparticles of the same 
material. For example, experimental values for MS of magnetite nanoparticles are between 30 – 
60 emu g-1, whereas this value for the bulk magnetite is reported to be as high as 92 emu g-1 [46]. 
The reason for such difference is not yet entirely clear and still under investigation. By reducing 
the applied magnetic field to zero, magnetization M of the domains decreases gradually to 
remanent magnetization – MR (Figure 2.6 point 3). The magnetization can be reduced to zero by 
applying a magnetic field in the opposite direction and a magnitude equal to the coercive field HC 
(Figure 2.6 point 4). At this point domains are demagnetized completely, but they can gradually 
begin to realign in the opposite direction if the external field is increased in the negative direction 
and reaches MS (Figure 2.6 point 5). Once again, by reducing the external field to strength zero, 
magnetic moments reach MR in the negative M axis (Figure 2.6 point 6). An applied magnetic 
field magnitude equal to coercive field HC in the positive direction will bring magnetization to 
zero and further increase of the field amplitude in this direction will trace the curve back to 
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positive MS (Figure 2.6 point 2). As shown in Figure 2.6, the magnetization curves for increasing 
and decreasing magnetic field amplitudes do not coincide and therefore the material demonstrates 
“hysteresis behaviour” – hysteresis is a Greek word for ‘a coming late’ – and hysteresis losses are 
expressed in the form of heat dissipated to the surrounding medium.   
 
Figure 2.6: Hysteresis curve of a multi-domain particle [45] 
In the case of fine ferri- and ferromagnetic single domain particles, such as iron oxide and cobalt 
respectively, thermal agitations are ignored when the difference between the maximum and the 
minimum energy per unit volume, set by the anisotropy energy of the particle, is larger than its 
thermal energy kT, where k is Boltzmann constant. Stoner-Wohlfarth’s calculations [50] 
demonstrate a narrow hysteresis curve for these single domain magnetic particles. When an 
external magnetic field is applied to magnetize and demagnetize such particles, energy is released 
in the form of heat. As in multi-domain particles, when the external magnetic field amplitude is 
larger than the anisotropy field, the anisotropy energy barrier is overcome and the magnetic 
moments will rotate onto the anisotropy axis closest to the external magnetic field direction. 
Further increase in the external field will lead to gradual alignment of the net magnetic moment 
with the external magnetic field direction until saturation. Figure 2.7A demonstrates this 
phenomenon. In this figure, red arrows represent the magnetic moments of the particle and green 
arrows represent the dominant ‘easy axes’. When external field H is applied, the magnetic 
moment follows the field direction. Once the external magnetic field is removed, the magnetic 
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moment takes a certain time to rotate back to its original lower energy ‘easy axis. Release of heat 
is therefore due to the fact that magnetisation here lags the applied external field.  
 
Figure 2.7: Relaxation Mechanisms 
Dashed lines represent the magnetic moments of the particle and solid lines represent the dominant ‘easy axes’ 
2.5.3 Superparamagnetic Nanoparticles 
In smaller single domain magnetic particles, called superparamagnetic nanoparticles – less than 
20 nm in diameter for Iron Oxide Fe3O4 (Magnetite) MNPs [51] – the difference between the 
magnetic moment maximum and minimum potential energy per unit volume of the particle is 
much smaller than its thermal energy kT. The orientation of the magnetic moments of these 
particles therefore, continuously changes due to thermal agitation [52]. In other words, thermal 
energy becomes significant enough to cause magnetic moments to randomly fluctuate in the 
absence of the energy from an external magnetic field. Due to this behaviour, as shown in Figure 
2.8 measured for iron oxide nanoparticles, these particles seem to lack hysteresis losses. However 
coercive fields HC do not rest at zero. Therefore, an extremely narrow hysteresis loss is formed 
which contributes into release of heat within superparamagnetic nanoparticles. 
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Figure 2.8: Hysteresis curve of an iron oxide superparamagnetic particle 
2.5.4 Relaxation Mechanisms 
By applying a moderate external magnetic field to superparamagnetic nanoparticles, the energy 
from the field drives the magnetic moments to rotate and aligns them with the magnetic field 
direction by overcoming the thermal energy barrier. Once the external magnetic field is removed, 
magnetic moments do not relax immediately but rather take some time to randomize their 
orientations. In fact, according to Néel relaxation mechanism, in superparamagnetic particles the 
alignments and relaxations are responsible for the generation of heat. According to Néel-
Arrhenius equation [52], the time 𝜏! for the magnetic moments to relax and rotate back to their 
thermal equilibrium orientation is given by  
𝜏! = 𝜏! exp 𝐾𝑉𝑘𝑇  (1) 
where K is the effective anisotropy constant, V is the volume of the magnetic core, kT is the 
thermal energy and 𝜏!  is a constant called ‘attempt time’ typically of a value equal to about 10-9 
to 10-11 seconds and is slightly field dependent, however this dependency is usually ignored [53].  
The third mechanism that may contribute to generation of heat within MNPs is Brownian 
relaxation. This type of relaxation mechanism causes both multi-domain and single domain 
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particles to heat up. In this case, shown in Figure 2.7B, the energy barrier for reorientation of a 
particle is given by rotational friction due to the rotation of the entire magnetic particle caused by 
the external magnetic field torque on the magnetic moment of the particle. Here, by applying the 
external magnetic field H the particle itself is able to turn towards the field direction. Brownian 
relaxation time  𝜏!, is defined by the rotational mobility of the colloidal magnetic particles and 
given by [54] 
𝜏! = 3𝜂𝑉!𝑘𝑇  (2) 
where η is the dynamic viscosity of the medium in which the particles are suspended and VH is 
the hydrodynamic particle volume. This volume, which is the volume of the magnetic core of the 
particle plus the coating shell around it, represents how the medium perceives the particle. The 
Brownian relaxation time is related to the applied magnetic field through the complex magnetic 
susceptibility. The relationship between magnetization M and the applied magnetic field H is 
expressed below by a parameter called magnetic susceptibility 𝜒    𝐌 = 𝜒  𝐇 (3) 
This parameter explains how magnetization varies with respect to the applied magnetic field. As 
described later, susceptibility consists of a complex (imaginary) and a real component. The 
Brownian relaxation time is accessible from the frequency (𝑓)  dependent complex susceptibility 
through the following equation [54]: 
𝜒(𝑓)   = 𝜒  !1− 𝑖  2𝜋  𝑓  𝜏! (4) 
where 𝜒!  is the DC susceptibility.  
For MNPs uniformly suspended in a liquid medium, relaxation times Néel 𝜏!  and Brownian 𝜏! 
take place in parallel [55]. Therefore the effective relaxation time 𝜏!""  or 𝜏 is given by 1𝜏!"" = 1𝜏! + 1𝜏! (5) 
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By simulating and plotting relaxation times versus particle size in Figure 2.9, (Matlab® code is 
given in Appendix A.1) for any given radius, it is clear that the shorter time constant dominates 
the effective relaxation time. It is worth mentioning that in highly viscous media, such as thick 
gel or tissue, the inverse of Brownian relaxation becomes very small and therefore, the effective 
time becomes dependent on Néel relaxation exclusively.  
Relaxation times are temperature dependent. However for mild hyperthermia at near 42 ºC, 
relaxation time constants does not alter by much, thus in this investigation the effect of small 
temperature elevations on time constants are considered negligible.  
 
Figure 2.9: Relaxation time vs. Particle size for MNPs 
2.5.5 Specific Absorption Rate (SAR) and Specific Loss Power (SLP) 
In hyperthermia, Specific Absorption Rate (SAR) is a measurement of the magnetic power 
absorbed per unit mass of the magnetic material (W g-1). SAR is proportional to the time rate of 
change of the temperature of the magnetic material and given by the following formula [56]:  
𝑆𝐴𝑅 = 𝑐  𝑉!𝑚 𝑑𝑇𝑑𝑡    (6) 
where c is the specific heat capacity of the sample (4185 J l-1 K-1 for water), m is the mass of the 
magnetic particles, 𝑉! is the total volume and !"!"   expressed in ºK s-1 is the temperature increment 
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which is experimentally derived from the linear regression of the initial data points seen in Figure 
2.10. 
 
Figure 2.10: Temperature vs. time for superparamagnetic magnetite nanoparticles 
Specific loss power SLP is a measurement of the magnetic power loss per unit volume of the 
magnetic material (W m-3). The loss power is transformed into heat and dissipated to the 
surrounding medium. SLP is obtained by multiplying SAR by the density  𝜌 (g cm-3) of the 
magnetic material (𝑆𝐿𝑃 = 𝑐 !"!"). 
According to the first law of thermodynamics, change in the internal energy  𝑑𝑈 of an adiabatic 
process (𝛿𝑄 = 0) is equal to the differential of magnetic work energy W on the system 𝑑𝑈 = 𝛿𝑄 + 𝛿𝑊 (7) 𝑑𝑈 = 𝛿𝑊 = 𝐇  .𝑑𝐁 (8) 
Where 𝑊 is the magnetic work done per unit volume of the magnetic material [55], 𝐇 is the 
external magnetic field strength and 𝐁 is the induction flux.  
As seen in Figure 2.11 [57], Equation (8) suggests that the change of B also lags behind that of H 
and just as seen in 2.5.2, this lag can cause the magnetic material to exhibit hysteresis.  
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Figure 2.11: Hysteresis of a magnetic material in B and H axes. 
Integration by parts of each segment of the hysteresis curve in respect to 𝑑𝑊 leads to 
𝑊 = 𝐇  .𝑑𝐁!!!!   𝑑𝑊 + 𝐇  .𝑑𝐁!!!!!   𝑑𝑊 + 𝐇  .𝑑𝐁!!!!!!   𝑑𝑊 + 𝐇  .𝑑𝐁!!!!!   𝑑𝑊= 𝐇  .𝑑𝐁   ∣!!!!− 𝐁  . 𝑑𝐇𝑑𝑊!!!! 𝑑𝑊 + 𝐇  .𝑑𝐁   ∣!!!!!− 𝐁  . 𝑑𝐇𝑑𝑊!!!!! 𝑑𝑊+ 𝐇  .𝑑𝐁   ∣!!!!!!− 𝑩  . 𝑑𝐇𝑑𝑊!!!!!! 𝑑𝑊 + 𝐇  .𝑑𝐁   ∣!!!!! − 𝐁  . 𝑑𝐇𝑑𝑊!!!!! 𝑑𝑊  
(9) 
𝑊 = − 𝐁  .𝑑𝐇 (10) 
Due to co-linearity of the fields, the angle between 𝐁  and 𝐇 reduces to zero and therefore the dot 
product vanishes and 𝐵 and 𝐻 become magnitudes [55].  
𝑊 = − 𝐵  𝑑𝐻 (11) 
𝐵 in Tesla is given by [45] 
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𝐵 = 𝜇! 𝐻 +𝑀  (12) 
where 𝑀 is the magnetization of the material (A m-1) and 𝜇!  is the permeability of free space 
(4𝜋×10!! T m A-1). Substituting Equation (12) into Equation (11), magnetic work can be 
expressed by 
𝑊 = −𝜇! 𝐻 +𝑀   𝑑𝐻 (13) 
When magnetization lags the field, the integration yields a positive result indicating conversion 
of magnetic work to internal energy [55], therefore: 
∆𝑈 = −𝜇! 𝑀  𝑑𝐻 (14) 
Therefore, the greater the closed area within the hysteresis loop, the greater will be the internal 
energy.  
As described in Section 2.5.4, heat is associated with the energy change through Néel relaxation 
due to magnetization and demagnetization of the superparamagnetic nanoparticles and rotation of 
the magnetic moments in an alternating magnetic field. Therefore, Néel relaxation can be seen as 
a form of hysteresis loss for superparamagnetic nanoparticles. For an applied time varying 
external magnetic field  
𝐻 𝑡 = 𝑅𝑒 𝐻!𝑒!"# = 𝐻! cos 𝜔𝑡  (15) 
And, 𝑑𝐻𝑑𝑡 = −𝐻!𝜔 sin 𝜔𝑡  (16) 
Susceptibility on the other hand, consists of both real (Equation 18a) and imaginary (Equation 
18b) components and are given by [55] 
𝜒   = 𝜒  ! + 𝑖𝜒  !! = 𝜒  !1+ 𝑖𝜔𝜏 (17) 
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𝜒  ! = 𝜒  !1+ 𝜔𝜏 ! 
𝜒  !! = 𝑖  𝜔𝜏1+ (𝜔𝜏)! 𝜒  ! 
(18a) 
 
(18b) 
which is dependent on DC susceptibility 𝜒!, angular frequency 𝜔 = 2𝜋𝑓 and relaxation time 𝜏.  
Magnetization as a function of time is therefore given in the following form:  
𝑀 𝑡 = 𝑅𝑒 𝜒  𝐻!𝑒!"# = 𝐻!   𝜒! cos 𝜔𝑡 + 𝜒  !! sin 𝜔𝑡  (19) 
Substituting Equation (16) and Equation (19) into Equation (14), the internal energy becomes 
∆𝑈 = −𝜇! 𝐻!   𝜒! cos 𝜔𝑡 + 𝜒  !! sin 𝜔𝑡    −𝐻!𝜔 sin 𝜔𝑡   𝑑𝑡  
= 𝜇!𝐻!!𝜔 𝜒! cos 𝜔𝑡 sin 𝜔𝑡 + 𝜒  !! sin! 𝜔𝑡 𝑑𝑡    (20) 
Integrating over one period, 1/𝑓, where 𝑓  is the frequency and equal to  𝜔/2𝜋, the Equation (20) 
leads to 
∆𝑈 = 𝜇!𝐻!!𝜔 𝜒! sin! 𝜔𝑡2𝜔 ∣!!!/!+ 𝜒  !! sin! 𝜔𝑡 𝑑𝑡   
= 𝜇!𝐻!!𝜔𝜒  !! sin! 𝜔𝑡 𝑑𝑡!!/!!  (21) 
where only the complex susceptibility component survives the integration.  
The specific loss power SLP, is equal to the internal energy multiplied by its frequency. 
SLP = 𝑆𝐴𝑅𝜌 = ∆𝑈  𝑓 = 𝜇!𝑓𝐻!!𝜔𝜒  !! sin! 𝜔𝑡 𝑑𝑡!!/!!  (22) 
where    𝜌 is the magnetic particle density and 𝑓  is the frequency of the external magnetic field. 
Solving for the above equation  
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SLP = 𝑆𝐴𝑅𝜌 = 𝜇!  𝑓  𝐻!!  𝜋  𝜒  !! (23) 
Hysteresis loop for ferromagnetic materials differs from a DC magnetic field to an alternating 
magnetic field. For constant magnetic field amplitude, as the frequency increases, the area of the 
hysteresis loop increases at first, and eventually decreases [58]. However to avoid complexity, 
here this factor has not been taken into consideration. 
Magnetic nanoparticles prepared with surface stabilizers form magnetic fluids, also known as 
ferrofluids, are suspended uniformly in a carrier liquid. These materials are single domain and are 
superparamagnetic. For such particles, relaxation mechanisms are dominant. From Equations (23) 
and (18b), SAR is expressed as [55] 
SAR = 𝜇!  𝑓  𝐻!!  𝜋  𝜒! 2  𝜋  𝑓  𝜏!""1+ 2  𝜋  𝑓  𝜏!"" !   1𝜌 (24) 
Figure 2.12 (Matlab® code is given in Appendix A.2) plots a simulation of the real and the 
imaginary components of the susceptibility as given in Equation (17). These components meet at 
the peak value of    𝜒  !!. In fact, as seen in Equation (21), the imaginary component of 
susceptibility is due to the phase difference between the applied magnetic field and the 
corresponding magnetization and therefore, it is responsible for generation of heat. Moreover, 𝜒  !! 
reaches its peak value when  𝜔𝜏 = 1. In the following sections this will help optimize MNPs core 
diameter for hyperthermia.   
 
Figure 2.12: Susceptibility components vs. Frequency 
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2.6 Magnetic Properties Suitable For Hyperthermia 
Magnetic properties suitable for hyperthermia are not only governed by the magnetic parameters 
of the MNPs but also by the physiological limitations that are set to protect living organisms 
against high magnetic fields. By optimising these properties, maximum SAR and thermal effect 
can be reached and therefore, fewer MNPs are required at the target area. In this section some of 
the magnetic parameters and limitations are discussed.  
2.6.1 MNPs Physical Parameters 
2.6.1.1 Size 
The size of the MNPs influences the value of SAR and therefore the thermal effect. As explained 
before, an area within a wide hysteresis loop leads to dissipation of more heat than does a narrow 
hysteresis loop. Assuming constant magnetization saturation MS, coercive field HC defines width 
of the hysteresis loop. There is a relationship between particle core size and the coercive field. As 
shown in Figure 2.13 [45], the HC is at its largest value for particles that are at the border of being 
single and multi-domain. Superparamagnetic nanoparticles show no hysteresis and therefore it is 
not surprising to see that they do not have any coercive field.  
 
Figure 2.13: Coercive field vs. particle diameter [45] 
Figure above suggests that particles resting on the border between single and multi-domain 
exhibit the highest value of SAR and thus are the best choices for hyperthermia. In a study, 
Zhang et al. [59] showed that due to technical and biocompatibility issues, the applied alternating 
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magnetic field is often much lower in amplitude than the field required to saturate all magnetic 
moments of MNPs. Conceptually, to benefit from heat generation by a complete hysteresis loop, 
particles have to magnetically saturate to extremely high fields on the order of a few thousand 
Oersted. Such fields may cause unwanted tissue heating, stimulation of peripheral and skeletal 
muscles and irreversible biological effects such as cardiac fibrillation [60]. Therefore, adequate 
magnetic field and frequency necessary to make use of the entire hysteresis loop would be too 
high to consider for hyperthermia. In addition, because an ensemble of multi-domain MNPs align 
randomly with the magnetic field, practically only 25% of the ideal maximum theoretical power 
may be dissipated as heat [61].  
According to Okawa et al. [62], under a moderate and physiologically tolerable alternating 
magnetic field, the single domain MNPs of 18 nm in diameter reached target temperature of 43 
ºC quicker than superparamagnetic and multi-domain MNPs. This claim is also in close 
agreement with the findings of Johannsen et al. [63] in which magnetite nanoparticles of 15 nm 
in diameter were used to elevate tumour temperature in vivo tests.  
As mentioned at the end of Section 2.5.5, the imaginary component of susceptibility is 
responsible for the heating of MNPs inside an alternating magnetic field. It was also shown that 
this component is at its highest value when 𝜔𝜏 = 1  where 𝜔 is the angular frequency and 𝜏 is the 
effective relaxation time. In highly viscous media such as tissue, the effect of the Brownian 
relaxation time on the effective relaxation time 𝜏 is negligible and Néel relaxation time 𝜏!  is the 
dominant factor [64]. Using Equation (24), Figure 2.14 (Matlab® code is given in Appendix A.3) 
simulates how SAR due to Néel relaxation behaves as size of the iron oxide MNPs varies. 
Frequencies of 20 kHz, 200 kHz and 2 MHz were randomly chosen to display the effect of 
frequency on SAR.  
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Figure 2.14: Power loss due to Néel relaxation vs. radius of MNPs 
2.6.1.2 Concentration of MNPs 
In steady state temperature difference ∆𝑇 is given by [65] 
∆𝑇 = SAR c  𝑅!3𝜆  (2.25) 
where c is the concentration of the MNPs (mass of the particles per tissue volume) and 𝜆 
represents the heat conductivity of a tissue volume with a radius R. From the above equation it is 
evident that higher concentration of MNPs in the tissue leads to higher  ∆𝑇. 
Earlier in Section 2.5.1 it was mentioned that one of the factors affecting the effective anisotropy 
constant K is the dipolar magnetic interaction generated by each particle in the external magnetic 
field on the neighbouring particles. Therefore, when the number of MNPs is altered, there will be 
a change in the dipolar interaction of MNPs. As a result, change in the concentration of MNPs 
will lead to a small change of the K value [66]. This alteration however, is considered 
insignificant in this investigation. 
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2.6.2 Limitations to Amplitude and Frequency of the alternating magnetic 
field 
Reversible hyperthermic disruption of the CNS barrier requires a precise delivery of well-
controlled thermal dose into a complex biological system of the brain that is equipped with its 
own thermoregulatory system. There are guidelines limiting the alternating magnetic field 
parameters (frequency and amplitude) to prevent deleterious physiological responses. These 
responses are stimulations of peripheral and skeletal muscles, possible cardiac stimulation, 
arrhythmia and non-specific inductive heating of tissue. The guidelines are obtained from 
scientific observations and epidemiological studies.  
For biomedical purposes, the frequency of the alternating magnetic field has to be higher than 50 
kHz to avoid neuromuscular electro-stimulation and lower than 10 MHz for appropriate 
penetration [67]. Available experimental data shows that the resting human body temperature can 
be elevated up to 1 °C if it is exposed to an electromagnetic field that produces a whole-body 
SAR of between 1 and 4 W kg-1 [60]. Eddy current loss produced by closed currents induced by 
alternating magnetic flux in a conductive tissue of sufficient area are responsible for this type of 
heating [68]. Harmful levels of tissue heating can be produced by exposure of the tissue to fields 
at higher SAR values.  Atkinson et al. [69] therefore, established an upper limit of 4.85 x 108 A 
m-1 s-1  for the product of field amplitude (H0) and frequency ( f ) for a single turn induction coil 
around the thorax of a normal size patient. For such body exposure, a tissue load threshold of 25 
mW ml-1 was recommended by Jordan et al. [68]. Power density absorbed by the tissue is given 
by 
𝑃!"##$% =   𝜋! 𝜇!  𝜇!!  𝜎!2 𝑓!𝑟!H!!                                                                (W  m!!) (26) 
where µ is the permeability and µ0 is the permeability of free space, σT is the conductivity of the 
tissue, f stands for frequency, H0 is the external field strength and r is the distance from the 
central axis of the body. Using the above equation and the upper limit to the product of the field 
amplitude and frequency, the following graph (Figure 2.15) is simulated and plotted (Matlab® 
code is given in Appendix A.4).  
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Figure 2.15: Biological limitation to field and frequency 
In the above graph, the curve represents the upper limit for H0 and f that can be used for patients 
with a body cross section of 10 centimetres in radius at tissue load limit of 25 mW ml-1. This 
simulation also took into account values for biological tissue conductivity ranging from 0.0144 S 
m-1 to 0.68 S m-1 as tabulated in [70] for frequencies in the range of 100 kHz to 1 MHz. Since 
eddy current power density is proportional to the square of the diameter of the induced current 
loops, the proposed upper limit can be accordingly larger for smaller body regions under 
alternating magnetic field exposure. For example, a higher limit of H0 x	  f = 4 x 109 A m-1 s-1 has 
been suggested for treatments of the breast cancer [71]. 
When an electromagnetic wave passes through the human body, as it heats the tissue it also 
declines in intensity. This is given by 
𝐼 = 𝐼!exp  (−2 ∝! 𝑥)                                              (W  m!!) (2.27) 
𝐼! < 100          (W  m!!) maximum safe incident intensity ∝!=∝! 𝑛!!/! 
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where I is the power per unit area transmitted through the tissue, x is the penetration depth of the 
tissue, ∝! is the total attenuation factor including scattering and absorption. 𝑛! is the incident 
frequency and ∝! averages ~5×10!! sec1/2m-1 for soft tissue [72]. According to Equation 23, at 
1000 MHz (microwave) more than 90% of power is lost in approximately 15 mm depth of the 
soft tissue; at 30 GHz incident power has lost 99% of its energy in less than 10 µm depth in the 
tissue. On the other hand, 67% of the energy is passed through a thickness of 10 cm tissue un-
scattered and un-absorbed at 160 kHz. This suggests a suitable frequency range (~100 kHz) for 
proper penetration of the alternating magnetic field and excitation of the MNPs at a deep target 
area. To simplify calculations, here the biological load is assumed to be isotropic and 
homogeneous and it’s cross section exhibits cylindrical symmetry to the induction coil. Also, the 
magnetic field within the coil and tissue load is assumed to be uniform and field penetration into 
the dielectric material is complete. Moreover, the tissue under study is far away from any metalic 
implants that could affect the field in any way. Last but not least, it is assumed that there is no 
axial electric field within the coil.  
Therefore, for proper penetration and efficient hyperthermic disruption of the CNS barrier by 
MNPs without harmful heating of the neural tissue caused by Eddie current losses, the alternating 
magnetic field amplifier is set to generate an amplitude of 7.6 kA m-1 at 150 kHz which falls in 
the alternating magnetic field exposure limit and allows for a penetration of up to 70% of the 
energy through a 10 cm thick tissue un-scattered and un-absorbed. 
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CHAPTER 3 PROJECT RATIONALE 
Progress in pharmaceutical research for drug delivery to the CNS is limited by its 
pharmacokinetics through a physiological barrier. Successful transient opening of this barrier for 
diffusion of therapeutics into the neural tissue could strongly support the feasibility of this 
treatment in a clinical setting. Therefore, the objective is to develop a localized, and transient 
technique to interrupt barrier functionality without activating its immune system. This technique 
will complement our MRN system for targeted delivery of therapeutic agents to the CNS. To 
realize this objective, the work was divided into 3 phases. In phase 1, an external heating 
apparatus was used to apply regional heat on the skull of an anaesthetized mouse (Chapter 4 – 
Article 1). The effect of heat on the permeability of the BBB was assessed using histological 
observation and tissue staining of Evans blue (a large fluorescent dye molecule). Results 
indicated a direct correlation between hyperthermia and BBB leakage as well as its recovery from 
thermal damage.  
In phase 2, hyperthermic opening of the BBB with MNPs in a rat model was investigated  
(Chapter 5 – Article 2). Extravasation of the Evans blue clearly supports the hypothesis. In this 
investigation, analysis of immunoreactivity indicated that the proposed technique is not 
associated with any inflammation.  
In phase 3 (Error! Reference source not found.), sodium fluorescein, a small fluorescent dye, 
and Evans blue dye were used to examine the integrity of the retinal tissue (BRB) after 
hyperthermia. In this part of the investigation, transferrin coated MNPs were used to enhance 
particle adherence on the surface of the endothelium during hyperthermia. Results indicate that, 
similar to BBB, application of mild hyperthermia by MNPs leads to transient leakage of the 
retinal barrier.  
Therefore, it is strongly believed that the aforementioned approach could potentially increase 
expectation for drug delivery to the CNS and may profoundly impact those affected by CNS 
disorders and their quality of life.  
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CHAPTER 4 ARTICLE 1 - TOWARDS MR-NAVIGABLE 
NANOROBOTIC CARRIERS FOR DRUG DELIVERY INTO THE 
BRAIN 
Seyed Nasrollah Tabatabaei, Sonia Duchemin, Helene Girouard, and Sylvain Martel 
Published in Robotics and Automation (ICRA), 2012 IEEE International Conference on Robotics 
and Automation , pp. 727-732. IEEE, 2012. 
4.1 Abstract 
Magnetic Resonance Navigation (MRN) relies on Magnetic Nanoparticles (MNPs) embedded in 
microcarriers or microrobots to allow the induction of a directional propelling force by 3-D 
magnetic gradients. These magnetic gradients are superposed on a sufficiently high homogeneous 
magnetic field (e.g. the Bo field of an MR scanner) to achieve maximum propelling force through 
magnetization saturation of the MNPs. As previously demonstrated by our group, such technique 
was successful at maintaining microcarriers along a planned trajectory in the blood vessels based 
on tracking information gathered using Magnetic Resonance Imaging (MRI) sequences from 
artifacts caused by the same MNPs. Besides propulsion and tracking, the same MNPs can be 
synthesized with characteristics that can allow for the diffusion of therapeutic cargo carried by 
these MR-navigable carriers through the Blood Brain Barrier (BBB) using localized hyperthermia 
without compromising the MRN capabilities. In the present study, localized hyperthermia 
induced by an alternating magnetic field is investigated for the purpose of transient controlled 
disruption of the BBB and hence local delivery of therapeutic agents into the brain. Here, an 
external heating apparatus was used to impose a regional heat shock on the skull of a living 
mouse model. The effect of heat on the permeability of the BBB was assessed using histological 
observation and tissue staining by Evans blue dye. Results show direct correlation between 
hyperthermia and BBB leakage as well as its recovery from thermal damage. Therefore, in 
addition to on-command propulsion and remote tracking, the proposed navigable agents could be 
suitable for controlled opening of the BBB by hyperthermia and selective brain drug delivery. 
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4.2 Introduction 
Brain tumours are extremely lethal and incredibly invasive and therefore, intervening with 
complex surgery is a top priority in most medical cases. Despite many efforts, drug delivery to 
the brain remains a challenge mainly because the Blood Brain-Barrier (BBB), which consists of 
endothelial cells that are tightly interconnected and cover all the interior of the cerebral vessel 
walls, is reputed to be insurmountable for most therapeutic molecules. In fact, nearly 98% of new 
drugs used in the Central Nervous System (CNS) to combat brain cancer and other chronic 
diseases cannot enter the brain following systemic administration [1]. On the other hand, 
systemic administration of toxic agents causes the active principles to distribute throughout all 
the organs. Therefore, while pathological regions are treated, they also promote side effects in 
healthy organs. 
The extremely selective permeability of BBB and high cytotoxicity of anticancer drugs reinforce 
the importance of non-invasive targeted drug delivery for brain tumours and other chronic brain 
related disorders. Previously, our team has shown successful local delivery and tracking of 
therapeutic agents encapsulated in miniaturized magnetic carriers in the liver of a living animal 
by the gradient field of a modified Magnetic Resonance Imaging (MRI) scanner [2, 3]. The 
proposed carriers consist of therapeutic molecules and aggregates of Magnetic Nanoparticles 
(MNPs) with relatively high magnetization saturation embedded inside a biocompatible and 
biodegradable polymer, which serves as a transport mediator in the vasculature. This 
encapsulation also functions as a protective shield and prevents cells from further exposure to 
toxic drugs during the carriers’ commute to a target area. 
Besides MR-propulsion and MR-tracking, the same MNPs can be synthesized to offer 
characteristics that will allow them to become magnetically excited by an alternating field and to 
release their energy in the form of heat to their surrounding area. Inside brain microvasculature, 
such heat may thermally disrupt an intact BBB thereby creating a transient opening for the 
therapeutic agents to cross into the brain tissue. In fact, it has long been recognized that 
hyperthermia, otherwise known as elevation of body temperature, can lead to intense cellular 
stress and cause temporal disruption of the BBB [4-7] as well as death of cancer cells by 
enhancing cell sensitivity and vulnerability towards more established forms of cancer therapy, 
such as radiation and chemotherapy [8]. Coincidentally, a widely suggested method of 
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hyperthermia is based on excitation of MNPs inside an Alternating magnetic field [9]. This 
technique makes use of the radiofrequency of electromagnetic waves to heat the MNPs and 
therefore it is just as effective in deep biological structures as it is at the surface.  
To our knowledge, hyperthermic disruption of the BBB via induction of MNPs by an Alternating 
magnetic field for drug delivery to the brain has not yet been reported. Here, the feasibility of this 
technique, as well as its integration with our pioneered MRI-based propulsion and tracking 
technique for intervention of microcarriers and microrobots in the vasculature are discussed. 
Furthermore, results in this study suggest that there may be a direct relationship between the 
elevated brain tissue temperature and the extent of the penetration of the desired drug molecules 
across the BBB. This implies that by controlling the amount of heat and exposure time, we can 
adjust the BBB opening for various molecular dimensions. Finally in this study, the recovery of 
the BBB from thermal damage is examined and investigated. Although this is a preliminary 
study, it is in light of such technique that non-invasive local drug delivery to the region of the 
brain may become possible. 
4.3 Background Information 
4.3.1 Blood-Brain Barrier (BBB) 
All capillaries in the mammalian body including humans are composed of endothelial cells. In 
the circumventricular organs, most of the capillaries are fenestrated to allow for rapid exchange 
of molecules such as the therapeutic agents between blood vessels and surrounding tissue. In the 
brain however, very complex inter-endothelial tight junctions interconnect the endothelial cells. 
The tight junctions seal the cell interspace and form a diffusion barrier that markedly controls the 
flow of molecules across the epithelium. In addition to the tight junctions, pericytes with smooth 
muscle-like properties constitute the BBB [10]. Only small electrically neutral lipid-soluble 
compounds with low molecular mass of less than 400-500 Daltons (Da), or those small 
electrically neutral lipid-soluble compounds with low air-water partition coefficients and an 
average cross-sectional area of 50 Å2, are able to diffuse passively through the BBB [11-13]. As 
mentioned before, this restrains admission of a considerable portion of pharmaceutical agents 
into the brain. For instance, currently many large drug molecules such as peptides, recombinant 
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proteins, monoclonal antibodies, antisense and non-viral gene medicines are ineffective for the 
brain [14]. 
One of the main functions of the BBB is to keep the neurotransmitters and agents that act in the 
CNS separate from the peripheral tissues and blood, so that similar agents can be used in the two 
systems without ‘cross-talk’ [15]. Also, because of the BBB’s large surface area (180 cm2 per 
gram brain [13]) and the short diffusion distance between neurons and capillaries (8–20 µm [16]), 
the extent to which a molecule enters the brain is determined only by the permeability 
characteristics of the BBB and that has a predominant role in regulating the brain 
microenvironment. That is why circumventing the BBB is a priority for any drug delivery 
mechanism to the region of the brain. Successful crossing of this barrier will have a profound 
effect on the treatment of many brain related disorders and therefore hyperthermia is being 
investigated for that purpose. 
4.3.2 Hyperthermia 
In modern oncology, hyperthermia generally refers to heating of organs or tissues in various 
ways to temperatures between 40°C and 45°C, at which point it causes moderate and reversible 
cellular inactivation [8]. In this regard, induction of MNPs by an AC field has been investigated 
for elevation of tissue temperature on a variety of fronts. Chief among those is the fact that the 
MNPs can act as very small heat sources once placed in an AC field, regardless of their depth 
inside the biological entity. On the contrary, other techniques such as RF, microwave and High 
Intensity Focused Ultrasound (HIFU), are not able to accurately target desired deep-seated 
tissues. 
During local hyperthermia to temperatures near 42°C in the region of the brain (ΔT = 5°C), 
morphological changes of individual endothelial cells in the monolayer lining of the micro-
vessels begin to cause the tight junctions between adjacent endothelial cells to loosen, therefore 
allowing transport of large molecules through intercellular pathway [17]. Fortunately, the BBB 
seems to have the capability to restore functionality after brief hyperthermic disruption [18]. The 
rate of this restoration however, depends on the amount of heat and the exposure time.  
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4.3.3 Magnetic Nanoparticles (MNPs) 
Among various methods of hyperthermia, whole body [5], microwave [6] and radiofrequency 
hyperthermia [7] are most commonly used to disrupt the BBB. In these techniques an entire 
region of the brain including neurons, astrocytes, vessel wall cells, and other glial cells are 
equally heated. In fact, this may be the reason for many undesirable acute side effects with 
hyperthermic disruption of the BBB by these techniques. Conversely, in the proposed 
hyperthermic disruption of the BBB by induction of MNPs inside an Alternating magnetic field, 
heat is exclusively dissipated to the ambient vessel wall cells by thermal conduction. 
Consequently, only the monolayer lining of the vessel walls and the endothelial cells are directly 
affected by the thermal stress.   
The Specific Absorption Rate (SAR) or heat generated by the MNPs is mainly caused by three 
major mechanisms; hysteresis loss, Néel, and Brownian relaxations. Particles’ physical properties 
as well as magnitude and frequency of the applied Alternating magnetic field determine the 
relative strength of each of these mechanisms. SAR is proportional to the time rate of change of 
temperature of a magnetic material and is given by the following formula [19]:  
𝑆𝐴𝑅 = 𝑐  𝑉!𝑚 𝑑𝑇𝑑𝑡    (1) 
In (1), c is the specific heat capacity of the sample (J·l-1·K-1), m is the mass of the magnetic 
particles (kg), 𝑉! is the total volume (m3) and !"!"  expressed in ºK·s-1, is the temperature increment 
which is experimentally derived from the linear regression of the initial data points obtained from 
the time varying temperature curve. In the steady state, the difference in temperature ∆𝑇 is given 
by (2) where C is the concentration of the MNPs (mass of the particles per tissue volume) and 𝜆 
represents the heat conductivity of a tissue volume with a radius R [20].  
∆𝑇 = SARC  𝑅!3𝜆  (2) 
From (2) it is evident that higher concentration of MNPs per unit volume of the tissue leads to 
higher  ∆𝑇. In reality, for most therapeutic applications, the relatively poor energy transfer 
efficiency of the MNPs, i.e. poor SAR, introduces a great obstacle that hinders full functionality 
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or demands large administration of the MNPs at the biological target location leading to an 
increase in possible side effects. Therefore, scientists have long been searching for MNPs with 
the highest possible SAR.  
In contrast to other forms of magnetization, superparamagnetism can prevent formation of 
nanoparticle clusters in the biological entity [9]. That is why ultra-small magnetite or 
superparamagnetic iron oxide (magnetite: Fe3O4) nanoparticles have been given special attention 
for hyperthermia. These particles are commercially available and their physical properties are 
vastly studied. In addition, magnetite nanoparticles have shown great biocompatibility, 
biodegradability and low toxicity [21]. The SAR value of these particles varies with respect to 
particle diameter and magnetic properties of the Alternating magnetic field. Our previous studies 
with superparamagnetic magnetite nanoparticles have shown promising results with regards to 
hyperthermia [22]. Table 3 summarizes some of the key parameters required to elevate the 
temperature of the brain tissue from 37 °C to 42 °C using commercially available particles. These 
parameters are induced from numerous in vitro experiments and simulations presented in [23]. In 
the same table, MNPs with much higher SAR but not yet commercially available are also 
reported.  
Table 3: Parameters required to elevate tissue temperature 5°C by 
hyperthermia of magnetite 
 Commercial 
[23] 
Ref [24] 
Composition Fe3O4 CoFe2O4 
Diameter (nm) 10 nm 9 nm 
Magnetism Superpara Superpara 
Coating PMO MnFe2O4 
Alternating field amplitude (kA m-1) 4.5 37.3 
Alternating field frequency (kHz) 160 500 
SAR (W g-1) 61.02 ~3000 
 
The main difficulty of localized hyperthermic disruption of the BBB by induction of the MNPs is 
transportation of the MNPs and therapeutic agents through the vasculature to a desired area of the 
brain. Several criteria have been foreseen for such transportation. First, the carrier must have the 
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ability to geometrically fit into the target microvasculature. Second, the carrier must allow for 
maximum MNPs concentration at the target area to reach sufficient thermal levels. It is also very 
important to consider factors such as immunological reactions, excessive toxicity, premature 
degradation and fast excretion of the carrier by blood enzymes, or unexpected capture by non-
targeted tissues that may affect the carrier behaviour.  Compositions such as polyglycolic acid 
(PGA), poly(lactic-co-glycolic acid) (PLGA), and various environment-sensitive hydrogels are 
some of the well-known biomaterials for this purpose [25]. 
4.3.4 MRI-Based Drug Delivery System 
Magnetic nanoparticles experience a thrust force when exposed to a gradient field. As seen in (3), 
this magnetic force, 𝐹magnetic (N) is directly proportional to the volume of the MNPs, 𝑉ferro  (m3) 
and their magnetization properties, 𝑀 (A·m-1) as well as the gradient of the magnetic field, ∇𝐵 
(T) [26].  
𝐹magnetic = 𝑉ferro .    𝑀  .∇𝐵 (3) 
Magnetic Drug Targeting (MDT) technique uses this to concentrate therapeutic drugs adsorbed, 
entrapped or covalently linked to aggregates of MNPs at a superficial target location following a 
local intravenous injection [27]. The main difficulty for this technique however, is that it lacks 
the ability to target deep tissues [9]. Therefore, instead of a conventional approach most often 
based on an external magnet, an improved alternative method based on the three dimensional 
gradient magnetic field of the MRI was proposed by our team [28]. In this technique, due to the 
large main magnetic field of the MRI, aggregates of the MNPs become magnetically saturated 
once inside the relatively high homogeneous field of a clinical MRI scanner and therefore, 
relatively small shifts in the gradient field can steer them towards a target anywhere in the tissue. 
Furthermore, the aggregates of the MNPs create a magnetic distortion on the images acquired by 
MRI sequences. Therefore, the same MRI platform is able to track the aggregates in real-time and 
confirm their presence at the target.  
In order to manoeuvre in the microvasculature, and to avoid fast degradation of the MNPs in the 
blood circulation system, as well as preventing them from dissociation, which greatly limits the 
thrust force and distortion for tracking purposes, the MNPs along with the therapeutic agents 
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must be encapsulated in biocompatible micrometer size carriers. Previously, our team was able to 
synthesize such complex microcarriers and to use them to target a specific region of the liver of a 
living rabbit [3] prior to the successful release of the therapeutic agent. The vascular structure of 
the liver however is very different from that of the brain. Therefore, the proposed micro-entities 
may require appropriate modifications before attempting MRN towards the brain. 
4.4 Methods 
Various studies evaluated the required amount of thermal exposure and duration for temporal 
disruption of the BBB based on imposition of thermal stress on the tight junctions [29, 30]. 
According to the findings of these studies, the ideal temperature for transient disruption of the 
BBB falls in the range of 40 °C – 45 °C for a period of 30 minutes. 
4.4.1 BBB Staining 
Staining of the BBB is a traditional method for evaluating BBB leakage. Evans blue, an 
exogenous dye tracer is used here to assess the integrity of the BBB following a hyperthermic 
disruption. The dye molecules are able to easily diffuse through the fenestrated endothelial cells 
of all capillaries except those of the brain due to a functional BBB. However, once the BBB is 
compromised, Evans blue enters the brain and it fluoresces with excitation peaks at 470 and 540 
nm and an emission peak at 680 nm [31]. Histological staining techniques can therefore reflect 
the extent of BBB leakage by studying the intensity of Evans blue dye in the brain.  
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Figure 4.1: Experimental Schematics 
a) Experimental schematics for Part i. b) The dorsal view of the brain. The cross in the middle 
represents the position of the heating point. c) Heating was done over the skull near Bregma. 
4.4.2 Experimental Procedure 
In the primary steps of this study, distribution of heat from an external heating device on the 
brain of living mice as well as feasibility studies in regards to hyperthermic disruption of the 
BBB were assessed. For this purpose, a two-phase in vivo experiment was executed: 
4.4.2.1 Phase i 
Five mice were separately anesthetised by intravenous injection of 40 mg kg-1 body weight of 
pentobarbital. Quickly after, each animal was positioned on a stereotaxic frame and the head of 
the animal was secured in place. Then, by removing the skin, the surface of the skull of the 
animal was exposed. At this point, four small holes (~1mm in diameter) were drilled into the 
skull at precise locations shown in Figure 4.1a. Next, fibre optic thermocouples were placed inside 
the holes. An external heating device was used to focally elevate the temperature of a small 
region of the brain near Bregma (see Figure 4.1c.) at a 40° angle for duration of 30 minutes. While 
the thermocouples recorded changes in temperature at specific distances (1, 2, 3, 5mm 
respectively) away from the heating point (see Figure 4.1b.), a rectal thermometer monitored the 
internal body temperature of the animal. Since the body temperature drops rapidly during 
anaesthetic state, each animal was placed on a thermal pad. In addition, a heating lamp was 
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placed 5 cm above the skull to keep the brain temperature at 37 °C during the experiment. As a 
consequence, the body temperature was always kept at 36.5 °C to 37 °C. 
The purpose of this experiment was to examine the thermal distribution in the brain tissue. This 
resulted in a thermal map of the tissue represented in Section IV. It is important to mention that, 
the environment in the experimental suite was kept thermally neutral during all experiments. 
4.4.2.2 Phase ii 
The purpose of this part of the experiment was to examine the feasibility of hyperthermic 
disruption of the BBB as well as its recovery period from thermal damage using Evans blue 
staining technique. Here, nine mice, each 6-8 weeks of age, were randomly divided into three 
identical groups. In contrast to the previous part, no holes were drilled into the exposed surface of 
the skull of these animals. In order to correlate temperature patterns with stains left from the 
Evans blue dye, the heating parameters for all groups were kept the same as was described in the 
first part of this experiment. 
4.4.2.2.1 Group I  
All mice in this group were intravenously injected with 40 mg kg-1 of body weight of 
pentobarbital and 4 ml kg-1 body weight 2% Evans blue dye. As in Part i, quickly after 
anaesthesia each animal was positioned on a stereotaxic frame where a thermal pad and the lamp 
kept the body temperature steady at near 37 °C. Just as before, the heating device was also placed 
at a 40° angle near and above Bregma and the exposure time was set to 30 minutes. All animals 
in this group were sacrificed one hour after injection of the dye. The animals’ brains were 
extracted and immersed in isopentane and kept on dry ice for further analysis.  
4.4.2.2.2 Group II  
To examine BBB’s ability to recover following hyperthermic disruption, all mice belonging to 
this group were prepared the same way as done in Group I except that the dye was injected 2 
hours after 30 minutes of thermal treatment had ended. Exactly one hour after injection of the 
dye, the animals were sacrificed and their brains were removed, immersed in isopentane and kept 
on dry ice for further study. 
4.4.2.2.3 Group III 
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All mice in this group served as controls and were injected with the Evans blue and before they 
were sacrificed. There was no staining of the dye found on the brain tissue of the mice from this 
group. 
4.4.3 Data Analysis 
Extracted brains were embedded in Optimal Cutting Compound where 50-micron coronal slices 
were made at −20 °C in a cryostat. Results are shown in the next Section. 
4.5 Results 
Results from the first part of the experiment are shown in Figure 4.2. In this figure, recorded 
temperatures from 1mm and 2mm distances away from the heating device quickly raised once 
heating started and rapidly plateaued at approximately 44.3 °C and 39.4 °C respectively. Also, at 
the distances of 3mm and 5mm away from the heating device, temperatures reached 37.8 °C and 
37.6 °C respectively.  
 
Figure 4.2: Temperature profile using the heating element. 
Elevation of temperature in the brain tissue of a mouse by an external 
heating element 
In phase ii, Evans blue dye was expected to have distributed throughout the entire body except 
the brain where they are forbidden entry prior to the hyperthermic disruption of the BBB. 
Following hyperthermia, the extracted brains from the animals of Group I revealed that 
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hyperthermia could indeed disrupt the BBB and allow entry of a large and heavy molecule such 
as Evans blue into the brain tissue. Figure 4.3 illustrates what the extracted brain from a mouse in 
this group resembles. As it is seen in this figure, the integrity of the BBB at where heat was 
applied was compromised leading to staining of that region of the brain. 
  
Figure 4.3: Appearance of the Evans blue 
dye near and around the heating point  
(Group I Animal #1) 
Figure 4.4: Brain Thermal Mapping 
A correlation between findings depicted in Figure 4.2 and the sketch shown in Figure 4.1b, lead to a 
thermal mapping of the brain in Figure 4.4. The temperature curves presented in Figure 4.2 indicate 
conduction of heat in the brain tissue regardless of the method heat has been produced. As 
mentioned before, MNPs are also able to create such thermal energy by relaxation processes. 
Thus, in the presence of micro-robots near the Bregma, distribution of heat generated by 
excitation of the embedded MNPs inside an Alternating magnetic field would be similar to Figure 
4.2. That is why the MNPs are considered the key component of the proposed micro-robots. 
Results from the histological examination of the extracted brains are tabulated and presented in 
Table 4. As seen, all animals from the first group except one (#3) were affected by hyperthermia 
where Evans blue left a visible stain on the brain tissue around Bregma. It is believed that 
technical problems caused the anomaly for animal #3. Animals from the second group that 
received a 2-hour recovery period, showed substantial lower leakage area compared to the 
animals in Group I. The location of the leakage of the BBB and visible stains were also very 
close to the heating device where according to Figure 4.2 must have reached to temperatures higher 
than 40 °C. Therefore, although the BBB seem to have partially or in case of Animal #1 fully 
recovered from hyperthermic disruption, the recovery period may have not been sufficient for 
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complete rejuvenation of the BBB. This requires further investigation. No evidence of BBB 
leakage for Group III could be found. 
Table 4: Histological examination of the BBB leakage of Evans blue dye 
 
Phase II 
Animal 
# 
Heating point position 
away from Bregma 
(mm) 
Diameter of BBB 
leakage of Evans blue 
(mm) 
Group I Hyperthermic 
Disruption 
1 1.6 4.22 
2 2.5 2.46 
3 1.66 0 
Group II Recovery from 
Hyperthermia 
1 2.3 0 
2 2.4 0.62 
3 2.2 1.98 
Group III Control 
1 N/A 0 
2 N/A 0 
3 N/A 0 
4.6 Discussion 
Overcoming the BBB is an important field of current research that seeks a technique to reach the 
inside of the brain. To achieve brain localized drug delivery and increased efficacy, this project 
suggests that the therapeutic agents must be administered to the brain by means no more invasive 
than an intravenous injection of microcarriers or microrobots consisting of MNPs and therapeutic 
agents capable of remote propulsion and tracking compatible with MRN, and on-command 
actuation in the brain. The results of the preliminary experiments presented in this paper indicate 
that temperatures of 38 °C and higher for an exposure time of 30 minutes are required for 
effective hyperthermic disruption of the BBB for crossing of large and heavy drug molecules. 
This crossing however is governed by the change of thermal energy or ∆𝑇, which according to 
(2), is directly depended to the value of SAR. Therefore, controlling SAR leads to controlling the 
level of BBB leakage. For hyperthermia by induction of MNPs inside an Alternating magnetic 
field, as intended in this project, the SAR mainly depends on the field frequency and amplitude. 
Varying these parameters therefore, results in adjusting the BBB leakage to our favour. Thus, we 
have shown that this technique not only can be highly localized, it also provides advanced control 
over the opening of the BBB into the brain. 
It must be mentioned that disturbance of the BBB at high levels may cause vasogenic edema and 
energy metabolic failure leading to subsequent structural brain damages. Evidently, the degree of 
44 
 
pathophysiological changes in the vascular system of normal brain tissue is dependent on 
temperature and duration of heating. To minimize local hypo-perfusion and local brain cell death, 
thermal dosage as well as exposure period must be carefully selected and performed in a 
controlled environment. 
4.7 Conclusion 
The main goal of modern pharmacology is the transport of drug molecules to specific targets 
while maintaining therapeutic efficacy. However, nearly 98% of drugs cannot enter the brain 
following systemic administration. Our group has previously pioneered a MRI-based drug 
delivery platform referred to as MRN that employs microcarriers or future microrobots capable of 
interventions in the vasculature. Here, our team is looking to equip these micro-entities with 
hyperthermic capabilities to disrupt the BBB and therefore be as effective in delivering 
therapeutic agents in the brain. This ability comes from the fact that these micro-entities rely on 
embedded MNPs that are excited once placed inside an alternating magnetic field. This excitation 
leads to moderate elevation of temperature and thus transient disruption of the BBB. In light of 
this technique, local drug delivery for various disorders such as brain tumours, psychiatric, 
neurological and neurodegenerative disorders may also become feasible.  
 
 
45 
CHAPTER 5 ARTICLE 2 - REMOTE CONTROL OF THE 
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Seyed Nasrollah Tabatabaei, Hélène Girouard, Anne-Sophie Carret, Sylvain Martel 
Published in Journal of Controlled Release 206 (2015): 49-57. 
5.1 Abstract 
Despite advances in neurology, drug delivery to the brain remains a substantial challenge. This is 
mainly due to the insurmountable and selective nature of the blood–brain barrier (BBB). In this 
study, we show that the thermal energy generated by magnetic heating (hyperthermia) of 
commercially available magnetic nanoparticles (MNPs) in the brain capillaries of rats can 
transiently increase barrier permeability. Here, the fluorescent Evans Blue (EB) dye was used to 
verify the BBB integrity. Results indicate a substantial but reversible opening of the BBB where 
hyperthermia is applied. Also, in this investigation, analysis of CD68 immunoreactivity, an 
indicator of inflammation, implies that this technique is not associated with any inflammation. 
We have previously investigated theranostic (therapeutic and diagnostic) capabilities of the 
MNPs, therefore, the findings presented in this investigation are particularly encouraging for a 
novel targeted drug delivery system to the brain. 
5.2 Introduction 
There has been a lot of ink given to the enormous progress that scientists around the world have 
made in the treatment of brain related disorders, yet drug delivery to the brain remains a 
challenge [1]. This is mainly due to the insurmountable and selective nature of the blood–brain 
barrier (BBB). This barrier consists of tightly interconnected endothelial cells that 
circumferentially form the interior lining of the cerebral vessel walls and prevents harmful 
substances from entering into the brain. By extension, most drug molecules and available 
therapeutics are not able to reach the brain. According to Pardridge [2], more than 98% of small 
molecules including therapeutics do not cross this barrier. The objective of the present 
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investigation is to provide proof that magnetic heating (hyperthermia) of magnetic nanoparticles 
(MNPs) by a low radiofrequency (RF) field can increase BBB permeability without perturbing 
other brain cells. In order to make this proposition a clinically viable technique, it is first essential 
to show that the opening of the BBB is local and it is entirely reversible. 
Recent literature is unanimous that improving access to the BBB holds substantial potential of 
improving therapeutic response to various brain related disorders including brain tumours [3]. In 
that regard, MNPs have been vastly researched for therapeutic and diagnostic purposes [4,13,12] 
as well as drug delivery to the brain [5–7]. The synergy between the current study and the 
ongoing research on MNPs could be pivotal in bringing more effective drug delivery technique 
with less toxicity to the clinic and to the market. 
The permeability of the BBB between adjacent endothelial cells (tight junctions) is known to 
increase in response to physiologically relevant temperature increase (38–39 °C) [8,9]. We have 
previously observed reversible disruption of the BBB in this temperature range on the surface of 
the brain [10]. For the first time in this study, we examined BBB permeability at the presence of 
moderate heat dissipated from magnetic heating of MNPs. The physics behind magnetic heating 
is beyond the scope of this paper, but in summary, a low radiofrequency (RF) field can 
magnetically excite MNPs to release energy in the form of heat to their surroundings through a 
mechanism called Néel relaxation [11]. Basically, each time the magnetic moments of the MNPs 
align with the alternating direction of the RF field, they release this energy once they relax back 
to their original direction. The present investigation focuses on the influence of magnetic heating 
of MNPs on BBB permeability in anesthetised rats. This preliminary experiment provides 
evidence that our proposed approach goes beyond former methods to access the brain tissue with 
higher spatial precision, advanced control and lower immune reaction. 
5.3 Material and methods 
5.3.1 Characterization of the MNPs 
MNPs with eight different coatings dispersed in separate aqueous solutions were kindly provided 
by Chemicell GmbH (Berlin, Germany). A small drop of diluted suspension from each sample 
was positioned on a 200-mesh carbon film and dried by air. TEM images were acquired on a Jeol 
JEM-2100 field-emission gun (École Polytechnique de Montréal, Canada) operated at 200 kV 
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(see Supplementary Information Appendix B, S. 2). The crystalline structure of the MNPs was 
analyzed by an X-ray diffractometer (X'Pertmodel from Philipps) using a Cu-Ka radiation (λ of 
1.541 Å) at 50 kV and 40 mA (see Supplementary Information Appendix B, S. 5). The 
superparamagnetic properties and magnetization of the MNPs were measured using a vibrating 
sample magnetometer (VSM) device (EV5, Magnetics, Université de Montréal, Canada) at room 
temperature (see Supplementary Information Appendix B, S. 3). 
5.3.2 Magnetic heating by radiofrequency (RF) field 
In this study, the RF field was set to 7.6 kA m-1 at 150 kHz by a 2-kW HotShot induction heating 
amplifier (Ameritherm Inc., New York). To apply this field, a custom-made coil was specifically 
designed to generate the required field strength and frequency fitted for the head of the animal as 
described in Supplementary Information Appendix B, S. 6. In order to determine which 
commercially available MNPs would provide higher heating profile, first various coatings of the 
MNPs were individually placed inside the RF field (see Supplementary Information Appendix B, S. 
1). The temperature rise for every sample was then recorded in respect to time. Finally, the 
sample with the best heating profile was chosen for the in vivo experiments. 
5.3.3 Animal protocol 
All animal procedures were performed according to the guidelines approved by the Ethics and 
Experimentation on Animal Committee (CDEA) of the University of Montreal. Twenty-four 
pathogen-free Sprague-Dawley rats (250–350 g) were examined to confirm the efficacy of the 
proposed approach. The animals were randomly separated into five groups, namely i) Control (n 
= 4), ii) Control RF (n = 4), iii) Normothermia (n = 4), iv) Hyperthermia (n = 8) and v) Recovery 
(n = 4). The appropriate exact protocol sequence for each group is tabulated in Table 5. 
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Table 5: Groups of animals and the appropriate procedure. 
I Control : EB CP    
II RF Control  : EB H2O-dd RF Field CP  
III Normothermia : EB MNPs CP   
IV Hyperthermia : EB MNPs RF Field CP  
V Recovery : MNPs RF Field Recovery EB CP 
 
EB: Intravenous injection of 0.3 µL 2% Evans Blue dye (30 min circulation time). 
CP: Cardiac perfusion of 0.9% saline and fixation solution. 
H2O-dd: Injection of the 60 µL distilled water via catheterization into the left MCA. 
RF field: Application of magnetic heating, exposure of the animal to the RF field (30 min). 
MNPs: Injection of the 60 µL PMO-coated MNPs via catheterization into the left MCA. 
Recovery: Two-hour recovery period during which the animal is anesthetised. 
 
• Normothermia: Anesthetised animals (2.5% isoflurane in Oxygen) in this group (n = 4) received 
a 0.3 mL intravenous 2% Evans Blue (EB) dye (Sigma, USA) via the tail vein. The dye was then 
circulated in the vasculature for 30 min. Each animal was then placed supinely on a platform at 
37 °C. Then the left common carotid artery (CCA), internal carotid artery (ICA), and external 
carotid artery (ECA) were carefully isolated (see in Figure 5.1) after a 1 cm incision in the middle 
of the neck. The distal portion of the ECA was permanently ligated with a 4-0 suture. 
Microvascular clips were applied to the CCA and the proximal parts of the ECA and ICA, and an 
incision was made between the ECA ligation site and the ECA clip. A 32G catheter (SAI, Illinois 
USA) was inserted into the ECA towards the CCA then the ICA while removing the 
microvascular clips. The distance between the middle cerebral artery (MCA) and the bifurcation 
between ECA and ICA is about 2 cm. Once the catheter was in place, an average of 60 µL 
poly(maleic acid-co-olefin) or PMO-coated MNPs (concentration: 12 mg Fe3O4 mL-1 double 
distilled water) was slowly injected. After injection, the catheter was slowly retrieved and the 
ECA was permanently occluded to avoid excessive blood loss. The animal was then kept alive 
under anaesthesia for 30 min. Quickly after, the animal was sacrificed via intra-cardiac perfusion 
of 60 cc warm 0.9% saline followed by 100 cc 4% paraformaldehyde (PFA) for the first 3 
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animals (RFU analysis) and 2% glutaraldehyde (stronger preservative for TEM analysis) for the 
last animal, to flush all the blood and EB dye out of the vascular system. Once perfusion was 
completed, the brain of the animal was extracted and placed inside a preservative solution (4% 
PFA or 2% glutaraldehyde respectively). 
• Hyperthermia: An average of 60 µL PMO-coated MNPs was injected into the left MCA as 
described for Normothermia. Each animal was then exposed to the RF field for 30 min. The 
animals were then sacrificed by an intra-cardiac perfusion of 60 cc 0.9% saline followed by 100 
cc 4% PFA for 7 animals (RFU analysis (n = 3) and immunohistochemistry (n = 4)) and 2% 
glutaraldehyde for the last animal (TEM analysis). 
• Recovery: Animals in this group (n = 4) received the same PMO- coated MNP dosage via the 
left MCA as discussed before. They were then exposed to the RF field for 30 min and kept alive 
under anaesthesia for 2 h. Then the animals were infused by 0.3 mL EB dye via the tail vein. 
After 30 min, the animals were sacrificed via an intra-cardiac perfusion as explained in 
Normothermia. 
• Control and Control RF: Animals without MNP injection in the Control RF group (n = 4) were 
exposed to the RF field for 30 min and sacrificed by intra-cardiac perfusion as described in 
Normothermia. Animals in the Control group (n = 4) did not receive MNPs and were not exposed 
to the RF field. These animals were sacrificed via an inter-cardiac perfusion 30 min after the dye 
was introduced in the vasculature. 
5.4 MNP localization using magnetic resonance imaging 
Images of the selected brain samples were acquired by a 7 Tesla magnetic resonance scanner 
(Agilent Technologies). The samples were securely placed inside a custom-made coil with 2 
channels and positioned in the middle of the magnet. To identify the MNPs in the brain samples, 
contrast-enhanced T2 spin-echo sequences were acquired using the following parameters: 
repetition/echo time, 3000 ms/20 ms; slice thickness, 1.00 mm; matrix size, 512 × 512; and pixel 
spacing (in plane resolution), 0.0488 mm2. 
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5.5 Analysis of BBB opening using Evans Blue 
Three brains from each group were sectioned coronally into 200 µm slices, from rostral to caudal 
on a vibratome (Leica, Germany) and collected on gelatin-coated glass slides. Sections were then 
mounted using a mounting medium and the EB staining was directly visualized and imaged with 
an epifluorescent microscope (Leica DM2000, Germany). The EB containing samples were 
imaged at 1× in phase-contrast mode with a 9 ms exposure time. Images were exported for 
luminosity analysis in tagged image file format (TIFF). 
 
Figure 5.1: The schematics for the experimental procedure for reversible hyperthermic opening of the BBB.  
a) Illustrates the MNPs being injected via a microcatheter that is inserted into the External Carotid Artery (ECA) and 
advanced to the Internal Carotid Artery (ICA) where its tip is finally positioned near the MCA in the Circle of Willis. 
b) The anesthetised animal is exposed to the RF field for 30 min. 
5.6 Evans Blue fluorescence data analysis 
Luminescence intensity thresholds for the contralateral images were computed and applied to 
their ipsilateral counterparts. The threshold was defined as the maximal luminescence intensity 
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for 95% of pixels in the contralateral side of the brain. EB concentration comparisons were 
assessed across all groups using one-way ANOVA and Bonferroni Multiple/Post-Hoc tests. 
Therefore, the ratio of the difference in the luminescence intensity between the two hemispheres 
with respect to the area of the left hemisphere was defined as the amount of fluorescence for each 
particular slice. These ratios were then added and averaged over a number of brain samples in 
each group (n = 3). 
5.7 Analysis of BBB opening using transmission electron 
microscopy (TEM) 
A group was selected for TEM imaging and fixated in 2% glutaraldehyde in PBS for 24 h. 
Transverse sections of the brain (200 µm thick) were produced with a vibratome and kept in 
antifreeze solution at −20 °C until processed for electron microscopy. The sections were washed 
with PBS, followed by a post-fixation with 1% osmium tetroxide in PBS for an hour at 4 °C. The 
brain sections were dehydrated in a graded series of ethanol (30–100%) and embedded in Epon. 
Ultrathin sections (70–80 nm) were cut using ultra-cut microtome and placed on copper grids for 
analysis. The grids were contrasted with uranylacetate and lead citrate and examined using a 
Philips CM100 electron microscope. 
5.8 Index of brain inflammation 
The detection of activated microglia/macrophages, an indicator of brain inflammation, was 
performed on 40-um-thick floating coronal sections from Hyperthermia group (n = 3). Sections 
were sequentially washed for 30 min with PBS. These sections were then incubated at 37 °C for 
45 min, followed by 1 h in blocking solution of PBS containing 10% BSA, 5% NGS plus 0.3% 
Triton X-100 at room temperature. For CD68 immunostaining, Mouse Anti-Rat CD68 
Monoclonal antibody (Millipore, USA) was used at a dilution of 1:150 in PBS blocking solution 
containing 0.5% BSA, 5% NGS plus 0.3% Triton X-100 at 4 °C overnight and then washed for 
30 min with PBS. For visualization by fluorescence, the sections were exposed to Alexa fluor 
546 Goat Anti-Mouse (Life technologies, USA) at a dilution of 1:200 in a PBS solution for 2 h 
on ice. Finally, the sections were rinsed and mounted on slides. Staining was observed under a 
20× objective by confocal laser scanning microscopy (Olympus). To ensure the accuracy of the 
procedure, these steps were followed on a positive control model. For that, an animal was 
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anesthetised by an i.p. injection of 0.53 mL pentobarbital (1.6 mL kg-1) and sacrificed 2 h after 
receiving an intra-cranial injection of 100 µL lipopolysaccharide (LPS). 
5.9 Results 
5.9.1 Physical properties of MNPs 
Magnetic properties of the MNPs play a critical role in their heating ability by an RF field. 
Superparamagnetic magnetite (Fe3O4) nanoparticles have shown great potential in this regard 
[12]. The magnetic heating ability of eight different magnetite nanoparticles was examined in 
vitro. Among these commercially available MNPs, poly(maleic acid- co-olefin) or PMO-coated 
MNPs show the highest thermal effect when excited by the RF field (data shown in 
Supplementary Information Appendix B, S. 1). This led to the selection of magnetite MNPs with 
PMO coating for the in vivo portion of this investigation. 
5.9.2 Characterization of MNPs 
Transmission electron microscopy (TEM) was used to measure the relative size distribution of 
the PMO-coated MNPs. As shown in Supplementary Information Appendix B, S. 4, these particles 
had a relatively widespread distribution ranging approximately from 3 to 18 nm in diameter, 
peaking at 11 and 13 nm. The crystal structure of these nanoparticles measured by X-ray 
diffractometer confirmed that these nanoparticles were in fact magnetite (see Supplementary 
Information Appendix B, S. 5). The vibrating sample magnetometer (VSM) measurements show 
low coercive field and lack of hysteresis which further proves the superparamagnetic nature of 
the nanoparticles. According to these findings, the PMO-coated MNPs were magnetically 
saturated (Ms) at 60.27 emu g-1 (data shown in Supplementary Information Appendix B, S. 3). 
5.9.3 BBB opening by magnetic heating 
All animals were randomly separated into five groups, namely i) Control, ii) Control AC, iii) 
Normothermia, iv) Hyperthermia and v) Recovery. The appropriate protocol for each group is 
tabulated in Table 1 and described in the previous section. Images of the extracted brains from 
each group are displayed in Figure 5.2. From the camera section of these images it is clear that in 
the case of Normothermia group where the thermal energy was not applied, the MNPs (seen in 
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black) remained inside the vasculature near the target. In Hyperthermia however, only a large 
blue stain that is resulted from diffusion of the EB dye into the tissue is apparent. Conversely, in 
Recovery neither the blue stain nor the black residue of the MNPs is visible (see Figure 5.2— 
Camera). 
5.9.4 MNPs as MRI contrast agents 
The presence of the MNPs in the tissue creates distortions on the images acquired by the MRI 
(see Figure 5.2— MRI). While after the application of magnetic heating (in Hyperthermia and 
Recovery), MNPs are no longer visible by the naked eye, the distorted images provide evidence 
that the MNPs in fact continue to exist in the target. Nevertheless, any small quantity of the 
MNPs can generate such distortions, therefore, we cannot speculate on the concentration of 
MNPs that has remained in that location. 
5.9.5 Fluorescent EB dye 
Selected images taken by the epifluorescence microscope are presented in Figure 5.2— 
Epifluorescence Microscope. From these images, Hyperthermia seems to have a higher rate of 
luminosity than other groups. To further examine this observation, brains from all experimental 
groups were sliced, imaged and analyzed. The result of this analysis is shown in Figure 5.3. In this 
figure, each column represents the relative fluorescent units (RFU) computed from all brain 
samples in a group. As expected for Hyperthermia (p < 0.05 vs. Control), the RFU is clearly 
higher than in any other group. Also in the case of Recovery (p < 0.01 vs. hyperthermia), the 
amount of fluorescent units counted after 2 h of recovery from magnetic heating is substantially 
lower than Hyperthermia and Normothermia. 
54 
 
 
Figure 5.2: Results of randomly selected brain samples from every experimental group is shown in this figure.  
i) Camera: images taken by a digital camera from 3 different angles. The fact that after intra-cardiac perfusion the 
EB dye is visible indicates that it has successfully diffused into the target brain tissue (Hyperthermia). In the case of 
Normothermia where the RF field was not applied, the MNPs (black) remained inside the vasculature. In the 
Recovery group, there is no indication of dye diffusion nor MNPs residue in the target area. ii) MRI: these images 
are taken by a 7 Tesla animal MRI. The MNPs are shown as distortions of the image (black) around the target tissue 
in the left hemisphere for the Normothermia, Hyperthermia and Recovery groups. iii) Epifluorescence Microscope: 
images from 200 µm slices (approximately 8.28 mm from interaural) are shown under this microscope. The 
fluorescent EB dye has a higher rate of luminosity in Normothermia than any other group. 
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Figure 5.3: Relative fluorescence unit  
This graph represents the relative fluorescence unit (RFU) for the Normothermia, Hyperthermia and Recovery 
groups. These values are in fact average of the sums of the amount of fluorescence that were computed from three 
brains in each group. Expectedly,  Normothermia (* p < 0.05 vs. Control) has the highest RFU value and Recovery 
(++ p < 0.01 vs. Hyperthermia) has the lowest one. 
 
5.9.6 TEM analysis of the BBB 
A brain from each experimental group was specially prepared for TEM imaging as described in 
the previous section. Some of these images are presented in Figure 5.5. For Hyperthermia and 
Normothermia, the MNPs are clearly visible inside the capillaries (shown by an arrow in Figure 
5.5b and c). Red blood cells and macrophages as well as cellular debris are also easily detected in 
these capillaries. There was no difference between images from the Control group and the 
Control RF group. Last but not least, TEM images from the Recovery group indicated a 
substantial decrease in the concentration of the MNPs inside the capillaries. 
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5.9.7 Brain immune response 
As described in the previous section, immunohistochemistry analysis was performed to detect the 
presence of the CD68 marker in brain tissue following BBB opening by magnetic heating. The 
presence of this marker indicates that the brain immune system has been activated. As illustrated 
in Figure 5.4a, samples from the injected brain with lipopolysaccharide (LPS) (positive control) 
were thoroughly lit by the CD68 fluorescent markers on activated microglial and/or microphages. 
Remarkably, other than expected evidence of monocytes in the capillaries (reticuloendothelial), 
no other trace of CD68 was found in the parenchyma of brains that were treated with magnetic 
heating. 
5.10 Discussion 
5.10.1 Transient opening of the BBB 
In this investigation, we propose a novel method to deliver therapeutic agents to the brain tissue. 
The objective of this study is to provide preliminary evidence that under the influence of RF field 
the thermal energy released from the MNPs can transiently increase BBB permeability. Our team 
has previously shown propulsion of the same MNPs in the vasculature towards a target site using 
a modified clinical MRI [20]. In this study, we used a simple cannulation technique to deliver 
MNPs to the surface of the target endothelium (the left MCA). We believe that the combination 
of the transient BBB opening and the MRI-based targeting technique can have a high impact on 
localized drug delivery to the brain. 
Due to the dismal prognosis of patients with brain related disorders, overcoming the BBB for 
drug delivery is highly desirable. Apart from surgery, which is the most invasive yet standard 
clinical approach for many types of brain tumours, the conventional administration of 
therapeutics is rigorously limited by poor drug penetration. In addition, some disorders are 
located in the middle of the brainstem, where they infiltrate amidst the nerves, thereby making 
surgery practically impossible. Transient disruption of the BBB can be attained by intra-arterial 
injection of an osmotic agent such as mannitol [14], or alkyl-glycerol [15]. However, osmotic 
agents lack targeted delivery and they can result in widespread BBB disruption with the potential 
for deleterious consequences. High intensity focused ultrasound (HIFU) is among prominent 
strategies for local delivery of therapeutics to the brain. This technique employs an acoustic 
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energy to vibrate intravenously administered micro-metric lipid-encased perfluorocarbon gas 
microbubbles (MBs) near the target endothelium. The oscillating MBs create a mechanical stress 
on the endothelial tight junctions thus allowing therapeutics to enter the brain [16,17]. Despite its 
enhanced synergistic effects, MBs have short half-lives in the vasculature and are quickly up-
taken by the reticuloendothelial system when circulating through the liver. On the other hand, 
when MNPs are deposited, they remain on the surface of the target endothelium for the duration 
of our technique. Furthermore, in the presence of HIFU, MBs undergo a phenomenon that leads 
to the formation of high pressure shock waves as well as fast-moving liquid jets [18], which can 
seriously damage the cellular membrane near a rigid surface in the brain. Also, the sound waves 
propagate non- linearly over a large region of biological structures before converging into a focal 
point, which may lead to undesirable side effects. The affinity of the MNPs on the surface of the 
target endothelium however, assures that the thermal energy is exclusively dissipated to the BBB. 
Therefore, this cell-specific approach ultimately minimizes potential side effects and overheating 
of the surrounding structures such as astrocytes and neurons. In addition, HIFU is also debatably 
performed without the benefit of real-time visualization. In other words, the time interval 
between intravenous administration of MBs and their arrival at the target location prior to the 
application of the acoustic energy is often roughly approximated. This and HIFU's current 
relatively large focal point (1 × 1 × 7 mm3 [19]) result in low spatial resolution for intervention in 
a highly sensitive organ such as the brain. The MNPs in our cell-specific method can be 
visualized as artifacts on the images of the MRI, and relatively low frequency RF field is just as 
effective in deep structures as it is at the surface of the brain. 
5.10.2 In vivo transient opening of the BBB by hyperthermia of MNPs 
To examine BBB integrity, all animals received an intravenous dosage of the florescent EB dye 
which is a tetrasodium diazo salt marker of albumin extravasation (MW 68 kDa [21]). Other dye 
molecules with different molecular weights will be used to further measure BBB opening in the 
future studies. We also used rat models due to their remarkable genetic overlap with humans and 
the availability of well-documented protocols. As shown in Figure 5.2— Camera, the dye 
molecules could not cross an intact BBB (Control, Control RF, Normothermia, and Recovery), 
but after magnetic heating of MNPs that were injected into the left MCA, the dye noticeably 
penetrated into the target brain tissue. Interestingly, while the exact time it may take for the BBB 
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to recover from magnetic heating is yet to be determined, after a two-hour recovery period the 
dye could no longer cross into the brain tissue. This signifies that the BBB is able to naturally 
redeem full functionality and recover from magnetic heating. In order to obtain a quantitative 
sense, the dye penetration in each experimental group was analyzed by an epifluorescence 
microscope and presented in terms of relative fluorescent units (RFU) in Figure 5.3. Remarkably, 
this figure suggests that the amount of dye diffused into the brain tissue after application of 
magnetic heating is over 4-fold larger than when it is not applied. 
Reversible opening of the BBB by magnetic heating of MNPs requires a precise delivery of a 
well-controlled thermal dose into a complex biological system of the brain that is equipped with 
its own thermoregulatory system. While theoretical calculation of the temperature near the BBB 
by thermodynamic equations is possible, exact empirical readings are practically impossible. 
Therefore, instead of relying on thermometers, MNPs and magnetic heating parameters are 
adjusted based on the feedback from the quantitative analysis of diffused dye into the tissue. For 
example, if the dye was unable to diffuse into the tissue after 30 min of magnetic heating, we 
could increase the exposure time or the MNP concentration to reach BBB opening levels. We 
understand that this trial and error method is not an optimal solution and it should be improved 
for future investigations. 
The accumulation of MNPs may have led to ischemic stroke, which would translate into BBB 
leakage [22]. However, despite evidence of accumulated MNPs as seen in TEM images shown in 
Figure 5.5b and c, these images do not show any sign of neuronal death or glial reactivity as 
observed in ischemic stroke. A recent study by Darwazeh et al. [23] suggests that mild elevation 
of brain temperature may have positive effects on the injured central nervous system. Regardless 
of ischemic occurrence, our results simply imply that the BBB leakage rate is substantially higher 
with magnetic heating and it is lower after recovery. 
The EB dye is considered a blood-borne molecule, which is at equilibrium between bound and 
unbound forms. A more thorough investigation using molecular tracers of different sizes would 
allow us to determine what is the size of the molecule that can be delivered by this method. Other 
future work include assessment of the BBB permeability for longer periods of time, use of 
neuronal and axonal markers to ensure the safety of this protocol, as well as surface modification, 
synthesis and optimization of the MNPs. Conveniently, the coating of the MNPs in this study 
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provides an adhesive property (hydrophobic/ hydrophilic interaction) to anchor onto the surface 
of the endothelium. The final concentration of the MNPs in the brain is highly dependent on the 
exact location of the injection site, as well as the blood flow rate at the time of injection. 
As shown in Figure 5.2— Camera, the MNPs are seen in the vasculature of only the Normothermia 
group. The MRI section of the same figure shows darker reflection for the MNPs in that group. 
While a multitude of factors may be at play, we speculate that the thermal energy facilitates MNP 
liberation from the surface of the endothelium in Hyperthermia and Recovery groups. Also, the 
reticuloendothelial (macrophage) clearance system (RCS) actively cleans the capillaries from the 
intruding MNPs (see TEM image on Fig. 5c). However, even after magnetic heating and/or the 
work of the RCS, some of the MNPs remain in the target location. This is evident from the 
images shown in Figure 5.2— MRI. In this figure, the MNPs are detected as distortions of the 
image because they greatly change the spin–spin relaxation rate (T2) of the surrounding water 
molecules in the tissue [24]. The exact quantity of the MNPs that remain in the target is yet to be 
investigated. Nevertheless, the images in Figure 5.5b and c suggest that the MNPs stay in the 
capillaries and do not cross the BBB. Conversely, in a recent in vitro study Bramini et al. [25] 
have reported significant crossing of the MNPs through the BBB. In our case however, other than 
a few lysosomal-like accumulations, we did not observe large accumulations inside the 
endothelium membrane (image not shown). This shows that different coatings, composition and 
size of the MNPs interact differently with the BBB. 
5.10.3 Primary immune response 
The complex effects of BBB opening on the brain immune system have important implications 
for clinical practice. In reaction to inflammation or homeostatic disturbances, microglial cells 
play a central role in immune responses of the brain environment. These cells present themselves 
as resting during local surveying of the microenvironment, and activated during an immune 
response. TEM images reveal the presence of these cells around the capillaries in resting state 
(Figure 5.4c). The morphological change of microglia from resting to activated state is largely 
associated with an increase in CD68 glycoprotein on the cytoplasm of the microglial cells. This 
marker is also expressed on various macrophages/monocyte lineage cells [26] and it is a 
commonly used antibody as a primary indicator of the immune response. Although we have not 
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yet fully verified this using all histological methods, the screening for CD68 marker showed no 
apparent immune response to our treatment in the brain tissue. 
It is evident that once the BBB is opened, the brain is exposed to blood-derived factors from 
which it is normally isolated. While there are other examples where the treatments for chronic 
and lethal diseases may temporarily jeopardize the patient's health as a whole, for a patient with 
severe brain disorder such as a lethal tumour, the benefit of having much needed therapeutics 
cross the BBB outweighs the risks. The unfortunate sequelea of chemotherapy-induced 
immunosuppression that seriously increases susceptibility of the patient to harmful pathogens is 
one of many examples. To minimize the entry of opportunistic pathogens to the brain, the extent 
of BBB opening must be engineered to exact molecular weight and size of the drug of interest. 
Adjusting the RF field parameters, the duration of the exposure to the field, as well as surface 
modification of MNPs, concentration, and volume will also enhance our control on the 
magnitude of the BBB opening and it will minimize possible pathological risks. 
5.10.4 Properties of the MNPs 
In addition to being multifunctional entities that make MNPs great candidates for targeted drug 
delivery [4,27,28], they have been extensively studied for their magnetic heating abilities as a 
complementary therapy that yields maximum benefit from radiotherapy and chemotherapy 
[5,29]. Among various chemical compositions, iron oxide MNPs (Fe3O4) have been given special 
attention due to biodegradability and low toxicity [30,31]. To minimize direct exposure of the 
iron oxide core while in biological settings, MNPs are often coated with a protective polymer 
shell. In addition, the coating decreases the dipole–dipole interaction between individual particles 
and prevents undesired aggregation [32]. Our investigation showed that among commercially 
available particles, polymaleic acid-co-olefin (PMO)-coated MNPs have the highest thermal 
effect (see Supplementary Information Appendix B S1). Other properties such as particle 
diameter and size distribution (mono-dispersed vs. poly-dispersed) can also play an important 
role in MNP heating ability [33,34]. To obtain maximum efficacy from the MNPs, these 
parameters should be well considered. 
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5.10.5 Regulations for safe RF Field 
Guidelines that limit the RF field parameters are set to prevent deleterious physiological 
responses. These responses are stimulations of peripheral and skeletal muscles, possible cardiac 
stimulation, arrhythmia and non-specific inductive heating of tissue. For biomedical purposes, the 
frequency of the field has to be higher than 50 kHz to avoid neuromuscular electrostimulation 
and lower than 10 MHz for appropriate penetration [35]. In addition, when an electromagnetic 
wave such as the RF field passes through the human body, as it collides with the tissue it declines 
in intensity. This decline is supported by a mathematical equation and it is further discussed in 
supporting information (Supplementary Information Appendix B2). We found frequencies 
ranging near 100 kHz suitable for proper tissue penetration and excitation of the MNPs at a target 
area deep in the brain. The tolerable exposure of living tissue to RF field is limited by its 
physiological constraints and depends on the field parameters. The ICNIRP guideline suggests a 
load threshold of 10 W kg-1 for the human head [36]. Plugging appropriate conductivity values 
for the human brain tissue (white matter, gray matter and skull) at 100 kHz [37], we obtained the 
upper limit curve for the RF field amplitude and frequency inside a cylindrical coil large enough 
to fit a human head (Supplementary Information Appendix B, S. 6). 
5.10.6 Prospect in targeted drug delivery to the brain 
Among all disorders, brain tumours are extremely lethal and incredibly invasive and despite the 
remarkable progress in pharmaceutical advances, the clinical translation of drug delivery to the 
brain faces a bottleneck. The inability to permeate through the BBB as well as lack of a localized 
therapy increases the cytotoxic risks of the therapeutics on normal tissue and thus hampers their 
efficacy. This is well apparent in the case of gliomas that account for approximately 70% of all 
malignant primary brain tumours and despite important advances in understanding their 
molecular pathogenesis, as well as in surgical resection and radiotherapy, they remain difficult to 
treat and the average survival length is only 12 to 15 months after diagnosis [38,39]. Therefore, 
highly selective permeability of BBB and limited pharmacological interventions, as well as high 
cytotoxicity of systemically administered therapeutics reinforces the importance of a controlled, 
localized and targeted remedy for brain related disorders. 
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Glioblastoma multiforme is the most common and invasive malignant primary brain tumour in 
children. With magnetic heating of MNPs that are attached to the BBB, we can evaluate the 
efficacy of orally administered chemotherapeutic drugs such as temozolomide on this tumour. In 
addition, transferrin has receptors specifically localized on the BBB and at higher concentration 
in and around brain tumours [40], therefore, the spatial specificity of transferrin-conjugated 
MNPs to open BBB at the vicinity of the tumour can be investigated. This strategy will allow us 
to optimize the MNP concentration required to control the BBB permeability and to use lower 
dosage of toxic therapeutic agents to combat the tumour. 
In contrast to other forms of drug delivery mechanisms, MNPs have shown great advantages in 
tumour targeting [28] and treatment [41]. In fact, our team has previously displaced and tracked 
therapeutics that were bounded to the MNPs in the vasculature of an anesthetised animal [20]. 
With the help of an applied 3D driving force from the magnetic fields of the MRI, aggregates of 
MNPs can be propelled towards a target region such as the brain. In addition, they can be tracked 
using the same distortion that they create on the images of the MRI shown in Figure 5.2— MRI. In 
this paper, we introduced magnetic heating ability of the same MNPs to yet expand their 
capabilities in drug delivery. We believe that the integration of the MRI-based propelling and 
tracking technique, as well as the BBB opening by magnetic heating provides the start of a non-
invasive localized and targeted drug delivery mechanism to the brain. 
5.11 Conclusion 
In this preliminary investigation, we introduced a method to transiently and locally open the 
BBB. It consists of the application of a regulated RF field to the locally administered MNPs in 
the brain. The MNPs in this configuration act as miniaturized heat sources that deliver the 
thermal energy uniquely to the endothelium with a higher spatial precision. We showed that large 
dye molecules are able to cross the BBB after application of this technique. We also showed that 
the BBB is able to naturally fully recover. Although the results shown here are only a proof of 
concept, the final goal of this research is to develop a mechanism that uses MRI and engineered 
MNPs to deliver therapeutics anywhere in the brain. The scientific ingenuity of the proposed 
technique combines simplicity, localized reversible drug delivery and accessibility throughout all 
regions of the brain, together with cell-specificity and apparent lack of primary immune response. 
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Potentially, this approach opens up a new window in search for a local drug delivery mechanism 
to treat various disorders including psychiatric, neurological and neurodegenerative disorders. 
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Figure 5.4: Immunohistochemistry and Microphages 
a) The activated microglia is shown by the fluorescent CD68 marker on lipopolysaccharide (LPS) injected brain 
sample (Positive Control) at the injection site. b) There is no evidence of activated microglia in the brain parenchyma 
of Hyperthermia treated rats. CD68 markers are only found on macrophages inside capillaries at the MNPs injection 
site. The brain capillary in this image is outlined by dotted lines. c) TEM image shows that macrophages (shown by 
arrows) have quickly gathered to start the clean-up process of the capillary from the MNPs. 
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Figure 5.5: Micrographs from TEM images 
a) Control: A cross section of a blood vessel in the cortex region. There was no difference between the Control and 
Control RF groups. The arrow indicated the location of a tight junction between two adjacent endothelial cells. b) 
Normothermia: A cross section of a blood vessel in the cortex region with MNPs. The MNPs are shown by an arrow 
inside a capillary. The black stars show the location of microglia cells around the capillary. c) Hyperthermia: After 
30 min of exposure to the RF field, the MNPs are still present in the capillary. The MNPs are shown by an arrow. d) 
Recovery: MNPs could not be seen in the images acquired by TEM, the brain structure seemed healthy after 2 h of 
recovery. 
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CHAPTER 6 COMPLEMENTARY RESULTS: BLOOD–RETINAL 
BARRIER 
6.1 Background 
6.1.1 Blood-Retinal Barrier (BRB)  
Similar to the brain microvasculature, the retinal capillaries consist of very complex inter-
endothelial tight junctions that interconnect the endothelial cells (Figure 6.1). The tight junctions 
seal the cell interspace and form a diffusion barrier that markedly controls the flow of molecules 
across blood vessel walls. This mainly constitutes the BRB [73]. A functioning BRB limits the 
passage of therapeutic molecules into the retina of the eye including majority of acting 
biomolecules [74].  
6.1.2 Ocular drug delivery  
Drug delivery to the eye can be classified into invasive and non-invasive approaches. The 
invasive approach consists of an intravitreal, intracameral, posterior juxtascleral, or retrobulbar 
injection of the medication into the eye. These approaches often lead to acute side effects and 
complete or partial lost of vision. The non-invasive drug delivery approaches include application 
of high drug dosage through topical, oral, systemic, or sub-tenon administration [17]. Despite 
encouraging results presented in some preclinical models, in the case of ocular tumours these 
approaches have been less promising. The results vary from increased normal tissue toxicity to 
only small increase in patients’ survival rate. That is because either the approach is extremely 
harsh for the ocular environment, or it is specific to a small group of drug molecules. An 
alternative approach from engineering’s perspective is to develop a mechanism to oversee a 
physical opening of the BRB. This mechanism should be non-invasive, localized, transient, and it 
should not cause activation of the ocular immune system.  
6.1.3 Localized disruption of the BRB 
Our team has been investigating a strategy to deliver therapeutics anywhere in the body including 
the brain and the eye. More specifically, this system combines the use of non-invasive colloidal 
carrier systems to magnetic targeting for reversible local disruption of the BRB. The MNPs in the 
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colloidal carrier system are the main key advantage in this approach. The intrinsic magnetic 
properties of the MNPs enable their use as contrast agents in MR imaging (MRI) techniques [75]. 
While the MRI uses this contrast ability to track the MNPs in the vasculature, we have shown 
that the gradient fields of the same MRI can also propel and direct them to a biological target 
location [54]. Once at the target, interventions with the BRB must remain exclusively at the 
surface of the endothelium. This minimizes excessive damage to the complex and sensitive 
environment of the retina. Interestingly, MNPs can act as miniaturized heat sources that, when 
under the influence of the radiofrequency field, dissipate a thermal energy directly and 
exclusively to the monolayer lining of the vessel walls and the endothelial cells. Our recent in 
vivo data in the brain suggests that thermal energy released by magnetic nanoparticles (MNPs) 
upon application of alternating magnetic field can transiently and locally open the endothelial 
barrier (tight junction). In this investigation, we applied the same technique in the retinal tissue of 
rat model. To enhance localization, the MNPs were commercially coated with human transferrin 
(Tf-MNPs). Transferrin has receptors specifically localized on the surface of the endothelium  
[23] therefore this strategy will maximize the concentration of MNPs at the target barrier.  
 
Figure 6.1: Experimental schematics 
The Tf-MNPs reach the left retina through the pterygopaletine artery. Hyperthermia of 
these particles under the influence of an alternating magnetic field increases BRB 
permeability. Traces of EB dye and Na-F are detected on extracted retinas.  
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6.1.4 Fluorescent dye molecules 
In order to evaluate barrier permeability during hyperthermia of MNPs, sodium fluorescein (Na-
F) and Evans blue (EB) dye were systemically injected in the blood stream. Na-F is one of the 
smallest (molecular weight of 376 Da [76]), and EB is one of the largest (molecular weight of 68 
kDa when bound to albumin [77]) fluorescent dye molecules that are commonly used to assess 
barrier leakage. In this investigation, Na-F was detected by spectrofluorometery and EB dye was 
counted by microscopic image analysis. 
6.2 Methods and experimental procedure 
6.2.1 Animal preparation 
All animal procedures were performed according to the guidelines approved by the Ethics and 
Experimentation on Animal Committee (CDEA) of the University of Montreal. Thirty-seven 
pathogen-free male rats (350-450 g) were examined to confirm the efficacy of the proposed 
approach. During the experiments, the body temperature of the animals were kept at 37 °C by 
means of a homoeothermic plate. 
6.2.2 Animal protocol 
Animals were randomly separated into two groups of Na-F (n=25) and EB (n=12) : 
Normothermia (n=8): Every animal in this group first received either 0.6 mL kg-1 10% Na-F 
dye (n=5), or 2 mL kg-1 EB dye (n=3), through the tail vein after being anesthetized (2.5 % 
isoflurane in Oxygen). The dye was then allowed to circulate in the vasculature for at least 30 
minutes. The animal was then placed supinely on a heated platform. The neck of the animal was 
shaved and the skin was cut about 1 cm in the middle. Then left common carotid artery (CCA), 
internal carotid artery (ICA), external carotid artery (ECA), and Pterygopalatine artery were 
carefully isolated (see in Figure 6.1). The distal portion of the ECA and the cerebral portion of the 
ICA were ligated with a 4-0 suture. A 32G needle (Hamilton, USA) was used to manually inject 
150 µL Tf-MNPs (concentration: 25 mg mL-1) into the CCA. After the injection, occluded 
arteries were opened and the animal was then kept alive under anesthesia for 30 minutes. Quickly 
after, the animal was sacrificed via intra-cardiac perfusion of 60 mL 0.9% sterile saline followed 
by 60 mL of 4% paraformaldehyde at a rate of 10 mL min-1 to wash out the dye remaining in 
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retinal capillaries. It was determined previously that this infusion rate does not damage the barrier 
[78]. Once perfusion was completed, the eyes of the animal were enucleated and conserved in 4% 
PFA overnight. 
Hyperthermia (n=8): To see the effect of the alternating magnetic field, under anesthesia, all 
animals in this group received either 0.6 mL kg-1 10% Na-F dye (n=5), or 2 mL kg-1 EB dye 
(n=3), through the tail vein and allowed circulating in the vasculature for 30 minutes. An average 
of 150 µL Tf-MNPs were then injected into the left CCA as described in Normothermia. Each 
animal was then placed inside the alternating magnetic field coils for 30 minutes. The animals 
were sacrificed after application of hyperthermia by an intra-cardiac perfusion as described for 
Normothermia. 
Recovery (n=8): To examine the ability of BRB to recover following hyperthermic disruption, 
all animals in this group received a dosage average of 150 µL Tf-MNPs into the left CCA as 
discussed before. They were then placed inside the alternating magnetic field for 30 minutes and 
kept alive under anesthesia for 2 hours. After the 2 hours recovery period, the animals received 
either 0.6 mL kg-1 10% Na-F dye (n=5), or 2 mL kg-1 EB dye (n=3) as described in previous 
groups. After 30 minutes, the animals were sacrificed via an intra-cardiac perfusion as explained 
before. 
Control and Background (n=13): Animals in the Control group (n=8) received either 0.6 mL 
kg-1 10% Na-F dye (n=5), or 2 mL kg-1 EB dye (n=3) and placed inside the alternating magnetic 
field for 30 minutes and sacrificed as mentioned before. Animals in the Background group (n=5) 
were only sacrificed via an intra-cardiac perfusion as explained before. 
6.2.3 Alternating magnetic field 
In this study, the alternating magnetic field was set to 7.6 kA m-1 at 150 kHz by a 2-kW HotShot 
induction-heating amplifier (Ameritherm Inc, New York). The current that conducted through a 
cylindrical 3-turn copper tube coil with 7 cm in diameter generated this field. 
6.2.4 Spectrofluorometery analysis 
All retinas with Na-F dye were extracted and placed upward in a black 96 well plate filled with 
100 µL phosphate buffer solution (PBS), and sent for spectrofluorometer reading (SPECTRAmax 
GEMINI XS, Molecular Devices) set at excitation wavelength of 480 nm and emission 
wavelength of 525 nm.  
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Figure 6.2: Mounted retinas are shown under the epifluorescence microscope.  
The fluorescent EB dye has a higher rate of luminosity in the left retina where hyperthermia of Tf-
MNPs has been applied. 
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6.2.5 Fluorescence microscopy 
All retinas with EB dye were extracted and placed on microscopy glass slides. Sections were then 
mounted using a mounting medium and the EB staining was directly imaged at the center of each 
retina with a fluorescent microscope (Leica DM2000, Germany). EB containing samples were 
imaged at 4x in phase-contrast mode with a 20 ms exposure time. Images were exported for 
luminosity analysis in tagged image file format (TIFF). Total input was computed by summing 
the suprathreshold pixels within the mask. This defined the area of the retina with EB dye. The 
threshold was defined as the maximal intensity for 95% of pixels in the right eye. EB 
concentration was assessed across all groups using one-way ANOVA and Bonferroni 
Multiple/Post-Hoc comparisons. 
 
Figure 6.3 : Spectrofluorometer readings of whole retinal tissue.  
The readings from the left retinas were normalized by the readings from the right retina. Then, those fall in a 
range between twice the standard deviation and the mean value were selected and averaged.  
 
0.8	  
1	  
1.2	  
1.4	  
Control	   Normothermia	   Hyperthermia	   Recovery	  N
ormali
zed	  Na
-­‐F	  read
ing	  (RF
U	  /	  ret
ina)	   Na-­‐F	  &luorescence	  reading	  by	  spectrophotometry	  	  
71 
 
6.3 Results 
6.3.1 BRB opening analysis by spectrofluorometery 
Spectrofluorometer readings are plotted in Figure 6.3. These findings clearly indicates that 
hyperthermia of Tf-MNPs facilitates diffusion of small Na-F dye molecules in the retinal tissue. 
Note that, the readings for Control, Normothermia, and Recovery groups are very similar but 
there is a 22.5% increase in Na-F detection when Hyperthermia is applied.  
6.3.2 BRB opening analysis by epifluorescence microscopy image analysis 
Various images of mounted retinal tissue are displayed in Figure 6.2. Results from image analysis 
done by a MatLab ® program is shown in Figure 6.4. In this figure, each column represents the 
relative fluorescent units (RFU) computed from all samples (n=3) in each group. To obtain this, 
retinas were mounted on glass slides imaged by an epifluorescence microscope.  
 
Figure 6.4: Results from microscopy image analysis for the EB dye.  
In this study, the left eye was the target site and the right eye served as contralateral. The luminescence 
intensity thresholds for the contralateral images were computed and applied to their left counterparts. The ratio 
of the difference in the luminescence intensity between the two eyes with respect to the size of the retina was 
defined as the amount of fluorescence for each particular group. These ratios were then added and averaged. 
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As expected for Hyperthermia, the RFU is clearly higher than in any other group. Also, in the 
case of Recovery, the amount of fluorescent units counted after 2 hours of recovery period from 
hyperthermic disruption of the BRB is substantially lower than Hyperthermia and Normothermia. 
6.4 Discussion 
The BRB is a highly organized multicellular complex consisting of endothelial cells that are 
tightly interconnected. This barrier markedly protects neurons by controlling the passage of the 
molecules into the retinal tissue. By the same line of argument, therapeutic molecules are also 
exempt from reaching the retinal tissue. For instance, in the case of retinoblastoma, an aggressive 
tumour that occurs in the developing retina of children, the main reason for failure of systemic 
administration of chemotherapeutics and subsequent enucleation (surgical removal of the eye) is 
the recurrence of subretinal or vitreous seeds, and lack of drug penetration, and high toxicity of 
the drugs on normal cells [79]. Given the disadvantages of current remedies, a localized, safe, and 
reversible strategy is therefore highly desirable. This strategy will reduce systemic toxicity 
thereby decreasing the need for hospitalization. Furthermore, a localized therapy allows the 
administration of significantly higher doses of therapeutics directly to the tumour site, which 
enhances the biological effect, improves the tumour control, and, thus, reduces the rate of 
recurrence. Recently, our team was able to use hyperthermia of MNPs to locally manipulate 
another similarly structured barrier in the CNS [80]. In this short presentation, we used the same 
technique to illustrate the effect of thermal energy on the BRB. As a part of a greater objective 
for targeted CNS drug delivery [30], in this investigation we used Tf-MNPs to target the left 
retina of the anaesthetized animals. The alternating magnetic field was used to elevate local 
temperature of the Tf-MNPs, and the induced thermal energy allowed both small Na-F molecules 
and large EB molecules into the retinal tissue. It is important to note that after two hours of 
recovery period, the BRB did not allow small Na-F molecules to diffuse into the neural tissue. 
This means that regardless of the molecular weight, the BRB was able to recover from the 
hyperthermic disruption.  
We have shown effective traversing of dye molecules across the BRB, however, a more thorough 
investigation using drug molecules and a tumour model would allow us to examine its 
performance in a therapeutic setting.  
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In the recent years MNPs have drawn a lot of attention for their theranostic (therapeutic and 
diagnostic) capabilities, therefore, our findings presented in this investigation are particularly 
encouraging for novel targeted drug delivery system to the eye. Evidently, hyperthermia with Tf-
MNPs and alternating magnetic field has increased the permeability of the BRB for the EB and 
Na-F dye. The barrier can then recover from the thermal stress and regain full functionality. 
Today, due to the functioning barrier, drug delivery to the CNS including the eye faces a 
bottleneck. The present study provides preliminary evidence that hyperthermia of MNPs can 
open new possibilities for localized drug delivery to treat various CNS-related disorders. 
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CHAPTER 7 GENERAL DISCUSSION  
The demanding function of the neural tissue requires an extremely stable environment. In fact, 
any small change in the composition of the interstitial fluid in the CNS plays a predominant role 
in regulating the brain microenvironment and thus neuronal activity. Therefore, the brain is 
conceived to protect itself from frequent fluctuations of extracellular concentration of hormones, 
amino acids, and potassium levels that occur after meals, exercise, or stress - as well as from 
toxic pathogens that may be circulating in the blood stream. This preventive defense mechanism 
is known as the blood-brain barrier (BBB) in the brain, and the blood-retinal barrier (BRB) in the 
retina. It consists mainly of tightly interconnected endothelial cells that carpet the inner surface of 
most blood vessels in the brain [7]. While the barrier provides a stable neuronal environment for 
a healthy CNS, it represents an insurmountable challenge for neuropharmacologists to combat 
CNS-related chronic disorders. According to Pardridge [15], more than 98% of all drug 
molecules are not able to cross this barrier. In the case of lethal brain neoplasm such as GBM, the 
tumour cells are located in the middle of the brainstem where they infiltrate amidst the nerves, 
making surgery practically impossible. Despite of weakened BBB in most developed tumours, 
the blood-tumour barrier (BTB) prevents many drugs to act upon the tumour which leads to low 
survival rate and poor quality of life. The BTB is a barrier that is formed between the tumour 
tissues and brain microvessels by highly specialized endothelial cells. In summary, during the 
development of the brain tumour, the cancer cells begin to invade the surrounding healthy tissue. 
As tumour cell clusters reach a certain volume, BBB gradually starts to collapse and the BTB 
begins to shape. With the deterioration of the tumour, progressive impairment of the BBB and 
angiogenesis, BTB becomes the main barrier to limit drug delivery. At this stage, the abnormal 
tumour neovasculature supports the growth and development of tumours by enhancing the 
permeability of the BTB. However, the cranial microenviroment and/or the tumour specificity 
make malignant tumours less permeable. Although the BBB is now compromised, at the 
proliferating tumour edge, this barrier persists with full functionality while the tissue could be 
well affected by the malignancy. Therefore, for an effective infiltration of the therapeutics, drugs 
still need to be delivered through the BBB to the surrounding tumour tissue. A recent effort 
presented in this doctoral thesis provides evidence for the emergence of a novel approach to 
overcome this problem. This technique uses MNPs in conjunction with an alternating magnetic 
field to transiently increase barrier permeability for drug delivery. In addition to novelty, the 
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findings confirm that the technique does not damage the neurovascular unit, i.e. neurons, 
astrocytes, etc. 
A current popular strategy is called HIFU that promises localized infiltration of therapeutics 
across the barrier. While this technique has shown promising, it offers low spatial and temporal 
resolution and it propagates non-linearly over a broad region of biological structures. Other 
physical stimuli approaches such as microwave or electromagnetic fields are among techniques 
that utilize hyperthermia to elevate the homeostatic temperature of the cerebrovascular unit. 
While elevation of temperature may create risks to the surrounding cerebrovascular unit, it offers 
an increase in CNS barrier permeability through a mechanism that widens the tight junctions 
[33], [81]. To minimize the risks, and increase spatial and temporal resolution, MNPs-induced 
hyperthermia is proposed. In this technique MNPs release a thermal energy when exposed to an 
alternating magnetic field. The heat can dissipate to adjacent endothelial cells (tight junctions) of 
the CNS creating an opening in the barrier [82], [83]. There are many advantages to this 
technique; chief among them is that the barrier leakage appears to be entirely reversible and it is 
not associated with an increase in CNS immune response. Also, the intrinsic magnetic properties 
of the MNPs enable their use as contrast agents in MRI techniques [75]. While the MRI uses this 
contrast ability to track the MNPs in the vasculature, the gradient fields of the same MRI can also 
propel and direct them to a biological target location [5]. Therefore, MNPs can offer non-
systemic delivery to spatially determined regions of the CNS using the MRN system [30]. This 
system provides physicians with a platform that allows targeting and delivery of medications to 
any specific location in the human body. In addition, MNPs induced hyperthermia is effective to 
target deep physiological regions. In this configuration, the alternating magnetic field parameters 
(field strength and frequency) are set to be compatible with human physiology and limitations of 
exposure to high magnetic fields. Furthermore, MNPs can be chemically engineered to 
specifically target the surface of the vascular endothelium by means of adhesion antibodies. For 
instance, transferrin has receptors specifically localized on the surface of the endothelium and at 
higher concentration around certain brain disorders [23]. This strategy could optimize the 
required MNPs concentration at the target site and lower side effects. 
Previously, hyperthermia of MNPs was thoroughly investigated and among number of different 
commercially available coatings, PMO coated particles showed highest heating profile (Appendix 
B, S. 1). In this doctoral thesis, hyperthermia of PMO coated MNPs was used to deliver otherwise 
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impermeable fluorescent dye molecules to the CNS in a rat model. Our preliminary results show 
that hyperthermia induced by MNPs translates to an increase in BBB permeability towards large 
albumin bonded Evans blue dye molecules in the brain. In this process, TEM images revealed the 
endocytosis of an infinitesimal amount of MNPs by the endothelium (Figure 7.1). Nevertheless, 
these images indicate that most particles were not able to cross the BBB (Figure 5.5b). The 
polymer coating (PMO) of the MNPs may have provided an adhesive property (hydrophobic / 
hydrophilic interaction) to anchor onto the surface of the endothelium. Data analysis including 
immunohistochemistry suggests that this technique goes beyond former methods to access the 
CNS with higher spatial precision and advanced control without perturbing surrounding 
structures of the cerebrovascular unit.  
In the ocular organ, transferrin conjugated MNPs were used to examine extravasation of sodium 
fluorescein across BRB and into the retinal tissue. Spectrofluorometery and microscopic imaging 
analysis strongly support the idea that hyperthermia of MNPs can transiently open BRB for 
penetration of therapeutic molecules into the retinal tissue.  
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Figure 7.1: Endocytosis of MNPs by the endothelium surface 
The arrows indicate few MNPs that are found in the lumen of the vessel while the rest of the MNPs on the top right 
corner could not penetrate across the BBB 
It is evident that once the barrier is opened, the CNS is exposed to opportunistic pathogens from 
which it is normally isolated. This is in fact a major obstacle. To address this alarming problem, 
barrier permeability must be engineered to molecular weight and size of the drug of interest. 
Adjusting the alternating magnetic field parameters, the duration of the exposure to the field, as 
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well as surface modification of MNPs, concentration, volume, and administration of antibiotics to 
the patient just before the intervention in a sterile environment could minimize possible 
pathological risks. The faith and the risk of MNPs in the blood stream especially in the brain is 
also among other alerting issues that needs to be well investigated. However, for patients with 
chronic and lethal CNS-related diseases the benefits associated with this technique seems to 
outweigh the risks. The collective assembly of hyperthermia of MNPs along with the MRN 
system makes MNPs a principal component of the proposed non-invasive targeted drug delivery 
mechanism to the CNS. Notably, when constructing the overall system, the limitations that the 
large one directional magnetic field of the MRI may introduce to the relatively smaller alternating 
magnetic field amplitude of the hyperthermia system (for example the distance between the MRI 
and the hyperthermia generator) should be well contemplated. Needless to say, it is clear that the 
proposed form of hyperthermia opens a door to new clinical trials involving otherwise very 
efficient anticancer treatments which do not readily cross the BBB and the BRB. The long-term 
goal is the development of a fully operational targeted drug delivery platform for the retina and 
the brain. By assessing the therapeutic efficacy of the hyperthermia technique in animal models, 
we have gotten closer to a great expectation for patients affected by CNS-related disorders.  
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CHAPTER 8 CONCLUSION 
The large number of individuals suffering from chronic brain diseases underlies the enormous 
potential growth of the neuro-pharmaceutical market. However, due to the presence of an intact 
endothelial barrier (tight junctions), most drugs do not enter the CNS following systemic 
administration. The present thesis has introduced localized thermal energy as a potential remedy 
to deliver therapeutics to treat various CNS disorders. In this technique, MNPs can act as 
miniaturized heat sources that, when under the influence of the alternating magnetic field, 
dissipate a thermal energy directly and exclusively to the ambient endothelial cells.  
After successfully propelling therapeutic agents encapsulated in magnetic micro-carriers [84] to a 
specific biological location in animal model by the gradient magnetic field of a modified clinical 
MRI scanner (MRN system) [30], we aimed to perform local drug delivery to the CNS. To 
achieve localized drug delivery and increase efficacy, this project advances the theme that the 
therapeutic agents must be administered to the CNS by means no more invasive than an 
intravenous injection followed by remote propulsion, controlled tracking, and on-command 
actuation. Clearly, more efforts are required to marry MRN with hyperthermia of MNPs before it 
becomes clinically viable, however, the work of this thesis opens a new window in search for a 
local drug delivery mechanism to treat various neurological disorders. 
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APPENDIX A – MATLAB ® PROGRAMING CODE 
A1           Figure 2.9: Relaxation time vs. Particle size for MNPs 
u_0=pi*4e-7;                         % volts.second/amp/meter   
Anisotropy = 2.64e4;                 %J m^-3 for magnetite 
Temperature = 297;                   %Kelvin room temperature 
Viscosity=1e-3;                      %Pa.s (kg/m/s);                   
t_0=1e-9; 
k=1.38e-23;                          % J/K (Boltzman Constant)(J=w.s)  
Density = 5.18;                      %g/cm^3 for Magnetite 
Ms_VSM =60;                          %emu/g  
Ms = Ms_VSM * Density * 1e3;         %A/m 
Coating = 40e-9;                     %meter 
Radius = 5e-9:1e-9:10e-9;            %nm 
  
for r=1:length(Radius) 
  
volume(r) = Volume(Radius(r)); 
  
%%% t_Neel  
  
GAMMA(r) = Anisotropy * volume(r) / k / Temperature; 
  
t_Neel(r) = (sqrt(pi) / 2) * t_0 * exp(GAMMA(r))/((GAMMA(r))^(1/2)); 
  
%%%% Brownian relaxation 
  
volume_hydro(r) = volume(r) * (1 + Coating/Radius(r))^3 ; 
  
t_Brownian(r) = 3 * Viscosity * volume_hydro(r)/k/Temperature; 
  
%%% t_effect 
  
t_effect(r) = t_Neel(r) * t_Brownian(r) /(t_Neel(r) + t_Brownian(r)); 
  
end 
  
semilogy (Radius, t_Brownian,'r','Linewidth',3) 
hold on 
semilogy (Radius, t_Neel,'b','Linewidth',3) 
hold on 
semilogy (Radius, t_effect,'g','Linewidth',3) 
  
title('Relaxation time vs. Particle size for MNP', 'FontSize',15) 
ylabel('\tau(s)','FontSize',15); 
xlabel('Particle Radius (m)','FontSize',15); 
text(8.6e-9, 1, '\tau_N_e_e_l', 'FontSize',15) 
text(5.5e-9, 1e-4, '\tau_B_r_o_w_n_i_a_n', 'FontSize',15) 
text(9e-9, 9e-5, '\tau_e_f_f_e_c_t', 'FontSize',15) 
set(gca,'FontSize',14); 
grid on 
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A.2         Figure 2.12: Susceptibility components vs. Frequency 
%%% Stoner-Wohlfarth Losses for small particles 
  
u_0=pi*4e-7;                        % volts.second/amp/meter   
  
Aisotropy = 2.64e4;                 %J m^-3 for magnetite 
Temperature = 297;                  %Kelvin room temperature 
Viscosity=1e-3;                     %Pa.s (kg/m/s) for ferrofluids 
volume_fraction=0.071;              %volume fraction solid 
Density = 5.18;                     %g/cm^3 for Magnetite 
Ms_VSM =60;                         %emu/g  
Ms = Ms_VSM * Density * 1e3         %A/m 
Radius = 6e-9;                      %meter         
Md = Ms / volume_fraction 
  
volume = Volume(Radius); 
Field = 10e3;                       %A/m 
Coating = 40e-9;                    %meter 
frequency = 0:1e5:1e7;              %Hz 
  
  
%Hydrodynamic diameter = shell thickness + core diameter + shell thickness = 
20 nm + 10 nm + 20 nm = 50 nm 
  
  
t_Neel = t_Neel(u_0, Anisotropy, Ms,volume,Temperature) 
t_Brownian = t_Brownian(Viscosity, volume, Radius, Temperature, Coating) 
t_effect = t_effect(t_Neel, t_Brownian); 
  
for f=1:length(frequency) 
    
Phi(f) = t_effect * 2 * pi * frequency(f);           %dimentionless  
Initial_Susc = Initial_Susceptibility (Ms,volume,volume_fraction, 
Temperature);        %dimensionless 
DC_Susc = DC_Susceptibility (Initial_Susc, Field, volume_fraction, Ms , 
volume,Temperature); 
Susc(f) = Susceptibility (DC_Susc,Phi(f)); 
sus_real(f) = DC_Susc / (1+(Phi(f))^2); 
sus_img(f) = Phi(f)* DC_Susc / (1+(Phi(f))^2); 
 
end 
 
semilogx (frequency, sus_img/DC_Susc,'r','Linewidth',3) 
hold on 
semilogx (frequency, real(sus_real/DC_Susc),'b','Linewidth',3) 
title('Susceptibility components vs. Frequency', 'FontSize',15) 
ylabel('\chi/\chi_0','FontSize',15); 
xlabel('Frequency (Hz)','FontSize',15); 
text(7e5, 0.4, '\chi_i_m_a_g_i_n_a_r_y', 'FontSize',15) 
text(8e5, 0.8, '\chi_r_e_a_l', 'FontSize',15) 
set(gca,'FontSize',14); 
grid on; 
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A.3          Figure 2.14: Power loss due to Neel relaxation vs. Radius of 
MNPs 
%%%%%%%%%%%%%%%%%%%%%%%% 
%%% Grain size dependence  
%%% of the loss power denisty  
%%% due to Neel-relaxation 
%%% for small magnetite 
%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
  
%%% SAR_Neel = (u0 f pi x0 (H)^2 2pi f t / [rho (1+(wt)^2)] 
%%% w = Angular_Freq 
%%% t = t_Neel 
  
  
clc 
clear all 
  
  
k=1.38e-23;                             % J/K (Boltzman Constant)(J=w.s)   
K=1.18e4;                               % Shape anisotropy Fe3O4 J/m^3 aspect 
ratio of 1.4 
u_0=pi*4e-7;                            % volts.second/amp/meter   
Temperature = 273+37;                   % Kelvin (Body temperature) 
volume_fraction=0.071;                  % volume fraction solid 
Density = 5.18;                         % g/cm^3 
H_field = 82.0;                         % Oe = 6.5 kA/m 
Magnetization = 40;                     % @ H = 82 Oe, (emu /g)                                         
Ms_emu_g = 90;                          % Magnetization saturation (emu/g) 
Ms = Ms_emu_g * Density * 1e3;          % A/m 
t_0 = 1e-10; 
Radius = 7e-9:1e-10:12e-9;              % meter 
Frequency = [2e4,2e5,2e6];              % Hz 
  
for i=1:length(Radius) 
     
     
    Volume(i)=4/3 * pi * (Radius(i))^3;                          % m^3 
    t_Neel(i) = t_0 * exp(K * Volume(i)/k/Temperature);          % second 
     
    %domain magnetization of a suspended particle 
    Md = Ms / volume_fraction;                
  
    %from Langevin relationship: 
    Initial_Susc(i) = u_0 * volume_fraction * (Md^2) * volume(i) / 3 / k / 
Temperature; 
  
    xi(i) =  u_0* Md * H_field * volume(i) / k / Temperature; %dimensionless 
    DC_Susc(i) = Initial_Susc(i) * 3 * (coth (xi(i)) - (1/xi(i))) / xi(i); 
     
    for f=1:length(Frequency) 
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        Angular_Freq(f) = 2 * pi * Frequency(f);      % radian 
         
        A=u_0*Frequency(f)*H_field^2*pi*DC_Susc(i)*Angular_Freq(f)*t_Neel(i); 
         
        B=1+(Angular_Freq(f)*t_Neel(i))^2; 
         
        SAR(i,f)=A/B/Density/1e6; 
         
    end 
     
end 
     
semilogy (Radius,SAR,'Linewidth',1.5); 
ylabel('SAR (W/g)','FontSize',15); 
xlabel('Radius (m)','FontSize',15); 
text(6.5e-9,3e1,'f = 2x10^6 Hz \rightarrow','FontSize',14); 
text(7.6e-9,3,'f = 2x10^5 Hz \rightarrow','FontSize',14);     
text(8.2e-9,0.2,'f = 2x10^4 Hz \rightarrow','FontSize',14);  
set(gca,'FontSize',14); 
%print -djpeg -r300 SARvsParticle_Jpeg_REVISED!!! 
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A.4          Figure 2.15: Biological limitation to field and frequency 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% this will calculate the amount of 
% SAR that is absorbed by body tissue 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%% 
u0 = pi*4e-7;           % permeability of vacuum (H/m) 
u  = 100*u0;            % permeability of  (H/m) 
Conductivity = 0.6;     % tissue conductivity (ohm^-1 m^-1) 
Radius = 10;            % radius of the region EMF is applied on (cm) 
  
density=0.8;            %average tissue density (g/cm^3) 
  
%limitation set by 'Usable Frequencies for Hyperthemria with Thermal 
%Seeds' --> 13.56 MHz at 35.8 A/m  for extended time --> 25 mW/ml 
 
Limit = 0.025;          %SAR (W/ml) or (W/cm^3) 
                        %Ref: Usable Frequencies in Hyperthermia with 
                        %Thermal Seeds: limit H0f <=  4.85x10^8 A/m/s 
% The resulting SAR value is 
% unlikely to produce a localized temperature increment of 
% more than 1°C in the limbs (Chatterjee et al. 1986; Chen 
% and Gandhi 1988; Hoque and Gandhi 1988), which has 
% been suggested as the upper limit of temperature increase 
% that has no detrimental health effects (UNEP/WHO/ 
% IRPA 1993). 
% In general, these have 
% demonstrated that exposure for up to 30 min, under 
% conditions in which whole-body SAR was less than 
% 4 W/kg, caused an increase in the body core temperature 
% of less than 1°C. 
  
% Summary of biological effects and epidemiological 
% studies (100 kHz–300 GHz) 
  
% Available experimental evidence indicates that the 
% exposure of resting humans for approximately 30 min to 
% EMF producing a whole-body SAR of between 
% 1 and 4 W/kg results in a body temperature increase of 
% less than 1 °C. Animal data indicate a threshold for 
% behavioral responses in the same SAR range. Exposure 
% to more intense fields, producing SAR values in excess 
% of 4 W/kg, can overwhelm the thermoregulatory 
% capacity of the body and produce harmful levels of tissue 
% heating. Many laboratory studies with rodent and nonhuman 
% primate models have demonstrated the broad 
% range of tissue damage resulting from either partial-body 
% or whole-body heating producing temperature rises in 
% excess of 1–2°C. The sensitivity of various types of 
% tissue to thermal damage varies widely, but the threshold 
% for irreversible effects in even the most sensitive tissues 
% is greater than 4 W/kg under normal environmental 
% conditions. These data form the basis for an occupational 
% exposure restriction of 0.4 W/kg, which provides a 
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% large margin of safety for other limiting conditions such 
% as high ambient temperature, humidity, or level of 
% physical activity. 
 
%initializing vectors of frequency and field amplitude 
freq=[]; 
field=[]; 
  
  
H_field=1e3:1e2:10e3;        %initial to final field (A/m) 
  
for i=1:length(H_field) 
  
    A=0;                  %initial to final (Hz) 
    B=1e6; 
    Frequency=A:1e4:B;         
     
    
    for ii=1:length(Frequency) 
  
              
       w(ii) = 2*pi*Frequency(ii);      %angular frequency 
        
       %W/cm^3 
       P_N(i,ii) =  1e-
6*(w(ii)^2)*(u0^2)*(Conductivity/8)*(H_field(i))^2*(Radius*1e-2)^2; 
        
       %W/g 
       P_N_2(i,ii)=P_N(i,ii)/density; 
        
         if P_N(i,ii) <= Limit && P_N(i,ii) >= (Limit-1e-3) 
             
           freq = [freq; Frequency(ii)]; 
           field = [field; H_field(i)]; 
  
           
         end     
        
    end 
        
end 
  
plot (freq,field,'LineWidth',2); 
grid on; 
xlabel('Frequency (Hz)','FontSize',15); 
ylabel('Field (A/m)','FontSize',15); 
title(['Field vs. Frequency for Loss Power limit of ',num2str(Limit*1000),' 
mW/ml'],'FontSize',15) 
text(2e5,8000,'Radius of the applied AC magnetic field = 10 
cm','FontSize',14); 
text(1.6e5,4800,'\leftarrow f = 160 kHz ','FontSize',14); 
text(1.9e5,4200,'H = 4.5 kA/m','FontSize',14); 
set(gca,'FontSize',14); 
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APPENDIX B – SUPPLEMENTARY INFORMATION 
B1. Magnetic Nanoparticles Heating Ability 
Magnetite nanoparticles (MNPs) purchased from Chemicell GmbH came in eight different 
coatings; Starch, Oleic acid, Polyacrylic acid, Poly (maleic acid-co-olefin), Polyvinyl alcohol, 
SiMAG Carboxyl and two types of uncoated MNP: anionic and cationic charge. Each sample 
was placed in a 2 kW induction heating machine. The primary purpose of this experiment was to 
see how various coatings would influence the temperature rise of the MNPs. Therefore, 0.5 ml 
MNP samples of the various coatings with a concentration of 12 mg Fe3O4  mL
-1 in distilled 
water were prepared in separate eppendorfs. Each sample was placed in a custom made isolation 
foam (Styrofoam) fitted to the inside of the copper tube coil. This coil was designed to generate a 
radiofrequency (RF) field strength of 2 kA m-1 at 160 kHz. A fibre optic temperature sensor 
(Reflex, SN: T18 217A, Neoptix Inc, QC, Canada) recorded temperatures of the sample at the 
center of the eppendorf every 15 seconds for a total time of 3000 seconds. A control sample 
containing deionised water was placed inside the coil to measure the effect of the RF field on the 
thermocouple, the eppendorf and the isolation foam. This effect was found to be negligible. 
Temperature increments as a function of time for all samples are depicted in Appendix B, S. 1. The 
images provided by Transmission Electron Microscopy (TEM) are presented below in Appendix B, 
S. 2 and show that some nanoparticles have different shapes and core size distribution than others. 
For these MNPs, the crystal diffraction patterns corresponded to magnetite (Fe3O4) composition 
(Appendix B, S. 5). The M - H curves provided by Vibrating Sample Magnetometer (VSM) show 
very narrow hysteresis losses and in some cases a complete lack of hysteresis losses is evident. 
These curves are depicted below in Appendix B, S. 3. From the images of TEM, the diameters of 
more than 630 single PMO coated particles were measured and recorded. The results are depicted 
in Appendix B, S. 4 and show a relatively wide size distribution ranging approximately from 3 - 18 
nm in diameter, peaking at 11 and 13 nm. 
B2. Limitations To The RF Field Parameters 
In Figure S6, the curve represents the upper limit for field amplitude and frequency that can be 
used for patients with a body (head) cross section of 10 centimeters in radius at tissue load limit 
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of 25 mW/cm. This simulation also took into account values for biological tissue conductivity 
ranging from 0.0144 S/m to 0.68 S/m as tabulated in [1] for frequencies in the range of 100 kHz 
to 1 MHz. Since eddy current power density is proportional to the square of the diameter of the 
induced current loops, the proposed upper limit can be accordingly larger for smaller body 
regions under RF field exposure. 
When an electromagnetic wave passes through the human body, as it heats the tissue it also 
declines in intensity. This is given by 
𝐼 = 𝐼!exp  (−2 ∝! 𝑥)                                              (W  m!!)  𝐼! < 100          (W  m!!) maximum safe incident intensity ∝!=∝! 𝑛!!/! 
Where I is the power per unit area transmitted through the tissue, x is the penetration depth of the 
tissue, αE is the total attenuation factor including scattering and absorption. nE is the incident 
frequency and αe averages about 5 x 10
-3 sec1/2/m for soft tissue [2]. 
To simplify calculations, here the biological load is assumed to be isotropic and homogeneous 
and it’s cross section exhibits cylindrical symmetry to the induction coil. Also the RF field within 
the coil and tissue load is assumed to be uniform and field penetration into the dielectric material 
is complete. Moreover, the tissue under study is far away from any metallic implants that could 
affect the field in any way. Last but not least, it is assumed that there is no axial electric field 
within the coil. 
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Appendix B, S. 1 - Temperature profile for MNPs with eight different coatings 
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Appendix B, S. 2 - TEM images of different coatings 
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Appendix B, S. 3 - VSM images of different coatings 
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Appendix B, S. 4 - Size distribution for the PMO – MNPs using Transmission Electron Microscopy imaging 
 
 
Appendix B, S. 5 - X-Ray diffraction for the PMO coated iron oxide nanoparticles 
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Appendix B, S. 6 - Biological limitation to RF field amplitude and frequency 
 
 
 
 
 
 
